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SUMMARY 
The mononuclear phagocyte system underlies the host response to myriad tissue 
injuries and thus represents a powerful therapeutic target to potentially augment healing in 
numerous clinical indications with unmet need. Mononuclear phagocytes, particularly 
monocytes and macrophages that infiltrate sites of sterile injury, are comprised of highly 
heterogeneous subpopulations with distinct functions and infiltration kinetics. Classical 
monocytes and classically-activated “M1” macrophages are generally “inflammatory” 
subpopulations that accumulate early, whereas non-classical monocytes and alternatively-
activated “M2” macrophages accumulate later and are generally “regenerative. Although 
M2 macrophages have received considerable attention as regenerative mediators, non-
classical monocytes are a novel cellular target for regenerative therapies.  
Our overarching goal is to effectively control the trafficking and function of 
circulating non-classical monocytes to enhance tissue repair. The objectives of this 
research are (i) to enhance the recruitment of non-classical monocytes to stimulate 
angiogenesis and arteriogenesis, processes critical to regeneration of vascularized tissues; 
(ii) to investigate synergy between immune-modulating molecules in non-classical 
monocyte recruitment and tissue vascularization; and (iii) to investigate the relationship 
between immune cell infiltration and rotator cuff injury-induced muscle degeneration. 
Implantable biosynthetic materials are powerful tools to achieve these objectives by 
enabling control over the spatial and temporal presentation of immune-modulating factors 
within an injury site.  
 xv 
To accomplish aim (i), we develop two novel PEGDA-based materials that control 
distinct chemokine signals locally within skin wounds. We show that PEGDA hydrogels 
functionalized with fractalkine-specific DNA aptamers can enrich endogenous fractalkine 
and increase accumulation of non-classical monocytes and M2 macrophages within skin 
wounds. Moreover, PEGDA hydrogels functionalized with a heparin derivative can 
encapsulate and release stromal derived factor-1a to achieve highly localized recruitment 
of non-classical monocytes and enhancement of tissue vasclarization. In aim (ii), we show 
that dual release of stromal derived factor-1α and the sphingosine analog FTY720 from 
heparin-PEGDA hydrogels causes synergistic accumulation of M2 macrophages and 
arteriogenesis. To achieve aim (iii), we use a murine model of severe rotator cuff injury to 
show that mononuclear phagocytes, particularly non-classical subpopulations, infiltrate 
supraspinatus muscle after injury, and that circulating monocytes contribute to 
supraspinatus degeneration. In contrast to results from aim (ii), we show that local delivery 
of FTY720 recruits inflammatory subpopulations of mononuclear phagocytes.  
The research presents novel biosynthetic materials that may aid soft tissue 
regeneration by recruiting pro-regenerative subpopulations of mononuclear phagocytes 
and stimulating vascularization. The work helps elucidate the role of chemokine signals in 
the recruitment and function of mononuclear phagocytes in soft tissue wounds. The study 
is the first to quantitatively analyze the infiltration of immune cell subpopulations after 





1. INTRODUCTION AND SPECIFIC AIMS 
Harnessing endogenous immune-mediated mechanisms of repair is a promising 
strategy to augment healing after traumatic or ischemic injury to myriad tissues. The innate 
immune system’s response to tissue injury is characterized by infiltration of mononuclear 
phagocytes, which orchestrate repair by clearing debris, remodeling extracellular matrix, 
facilitating growth of new and existing blood vessels, and signaling to circulating and 
parenchymal cells that help restore the native tissue composition. Mononuclear phagocytes 
are comprised of highly heterogeneous subpopulations that exert divergent effects on 
injured tissue during pathogenesis and regeneration. Dominant presence of non-classical 
monocytes and alternatively-activated M2 macrophages over classical monocytes and 
classically-activated M1 macrophages is associated with superior healing outcomes. 
Implantable drug-eluting biomaterials represent promising platforms for immune-
regenerative strategies because controlled drug delivery can facilitate spatial and temporal 
control over presentation of biological factors within injured tissue. The overarching goal 
of this research is to develop implantable materials that induce pro-regenerative immune 
cell responses within injured tissue by controlling the recruitment and activity of non-
classical monocytes. The overarching hypothesis of this research is that biomaterial-
mediated recruitment of non-classical monocytes enhances soft tissue repair. We evaluate 
the ability of two novel hydrogel platforms to enhance monocyte-assisted angiogenesis 
using the dorsal skin window chamber model of excisional skin injury, which enables 
concomitant assessment of immune cell recruitment and vascular remodeling. Moving 
toward a musculoskeletal indication with significant unmet clinical need, we investigate 
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the role of mononuclear phagocytes in rotator cuff muscle degeneration and evaluate the 
ability of drug delivery strategies to generate pro-regenerative immune responses and 
inhibit muscle degeneration. 
 
Aim 1. Evaluate monocyte recruitment and vascularization of injured skin in 
response to manipulation of chemokine signals using biosynthetic materials.  
Non-classical monocytes express high surface levels of CX3CR1 and CXCR4 
chemokine receptors compared to classical monocytes and thus migrate up gradients of the 
cognate ligands fractalkine (FKN) and stromal derived factor-1α (SDF-1α). The objective 
of this aim is to develop and evaluate biosynthetic materials to harness the FKN-CX3CR1 
and SDF-1α-CXCR4 signaling axes to recruit non-classical monocytes. First, we 
hypothesize that PEGDA hydrogels functionalized with FKN-specific DNA aptamers 
enrich endogenous FKN and recruit non-classical monocytes to injured skin. To address 
the hypothesis, aptamers and aptamer-functionalized hydrogels (“aptagels”) are evaluated 
for their ability to bind and release mouse FKN in vitro using surface plasmon resonance 
and ELISA. To evaluate effects in vivo, aptagels are implanted in the mouse dorsal skin 
window model. Endogenous FKN enrichment is measured by ELISA, and mononuclear 
phagocyte recruitment is measured by flow cytometry and confocal intra-vital microscopy. 
Next, we hypothesize that on-site SDF-1α delivery from N-desulfated heparin-
functionalized PEGDA hydrogels (Hep-N-PEGDA) recruits non-classical monocytes and 
stimulates angiogenesis in injured skin. Hep-N functionalization combines the growth factor 
sequestration and protection activity of heparin with the reduced anticoagulant activity 
afforded by N-desulfation. After assessing bioactivty of SDF-1α released from Hep-N-
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PEGDA hydrogels in vitro, gels are implanted in the mouse dorsal skin window model. 
Early recruitment of bone marrow-derived cells is assessed using GFP+ bone marrow 
chimeras and whole mount immunofluorescence. Mononuclear phagocyte recruitment is 
evaluated at multiple time points using complementary methods including flow cytometry, 
intra-vital microscopy, and whole-mount immunofluorescence. Concomitant angiogenesis 
and arteriolar expansion are assessed using whole-mount immunofluorescence and intra-
vital brightfield microscopy.  
 
Aim 2. Investigate synergy between chemokine and sphingolipid signals in achieving 
non-classical monocyte recruitment and vascularization of injured skin.  
Previous results from our lab and others suggest that dual stimulation of CXCR4 
and S1PR3 signaling axes may act synergistically to enhance the migration and pro-
regenerative activity of non-classical monocytes/macrophages. To investigate suspected 
synergy, we engineered a dual-affinity heparin-based biosynthetic hydrogel to co-release 
SDF-1α and the S1PR3-targeted small molecule FTY720. The hydrogel exploits the 
growth factor binding activity of heparin in tandem with the lipid chaperone activity 
albumin to encapsulate two molecules with disparate physicochemical properties. We 
hypothesize that dual release of SDF-1α and FTY720 from Hep-N-PEGDA hydrogels 
synergistically enhances non-classical monocyte recruitment and tissue vascularization. 
First, we assess migration of bone marrow-derived cells toward SDF-1α and FTY720 
released from Hep-N-PEGDA hydrogels in vitro. Gels are implanted in the mouse dorsal 
skin window model as in Aim 1. Mononuclear phagocyte recruitment is evaluated at 
multiple time points using complementary methods including flow cytometry, intra-vital 
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microscopy, and whole-mount immunofluorescence. Concomitant angiogenesis and 
arteriolar expansion are assessed using whole-mount immunofluorescence and intra-vital 
brightfield microscopy. 
 
Aim 3. Investigate the relationship between immune cell infiltration and rotator cuff 
muscle degeneration.  
Muscle degeneration caused by rotator cuff injury is a significant clinical problem 
that lacks effective treatments and understanding of the underlying pathogenesis. Growing 
evidence suggests that immune cell infiltration may contribute to rotator cuff muscle 
degeneration. The objective of this aim is two-fold: to elucidate the role of immune cell 
infiltration in supraspinatus degeneration, and to evaluate drug delivery strategies for 
generating a protective immune response. We hypothesize that infiltration of classical 
mononuclear phagocyte subpopulations contributes to muscle degeneration after rotator 
cuff injury. To address the hypothesis, we utilize a murine model of severe rotator cuff 
injury. Infiltration of innate and adaptive immune cell subpopulations are measured by 
flow cytometry and the cytokine milieu is assessed by multiplex immunoassay. The role 
of circulating monocytes in supraspinatus degeneration is evaluated by depleting 
monocytes with liposomal clodronate. Lastly, we locally deliver SDF-1α and FTY720 to 
injured supraspinatus and assess the effect on immune cell recruitment, cytokine 




2.1. The mononuclear phagocyte system underlies the host response tissue injury  
The innate immune system plays a central role in the body’s response to numerous, 
diverse injuries that cost lives, decrease quality of life, and burden the healthcare economy. 
Development of novel therapeutic interventions that leverage endogenous immune-
mediated mechanisms of repair may accelerate or augment healing after traumatic injury 
to musculoskeletal[1], nervous[2-5], and cutaneous tissues[6, 7] and ischemic injury to 
cardiac[8] and nervous tissues[9]. The immune response to sterile injury and tissue trauma 
is characterized by the infiltration of mononuclear phagocytes to clear debris, remodel 
extracellular matrix and vasculature, and signal to circulating and parenchymal cells that 
help restore the native cellular and matrix composition[10, 11]. Loss of function studies 
show that early mononuclear phagocyte input is necessary for regeneration of amputated 
salamander limbs[12] and zebrafish tail fins[13], suggesting that mononuclear phagocytes 
orchestrate complex regeneration programs requiring the coordination of multiple tissues 
types. 
 
2.2. Origin of mononuclear phagocytes in tissue injury 
Sterile injury causes inflammation and the associated accumulation of macrophages. 
Expansion of the macrophage pool during inflammation is driven by differentiation from 
infiltrating monocytes[14, 15]  and/or proliferation of tissue-resident macrophages[16, 17]. 
Tissue-resident macrophages are derived from either adult monocytes during homeostasis, 
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or embryonic origins[18]. Embryonically-sourced macrophages may stem from yolk-sac 
endothelium, fetal liver monocytes, and erythroid-myeloid progenitors and have been 
identified in heart, lung, brain, skin, and liver. Origins of macrophage populations during 
inflammation are highly context dependent. TH2-linked infection is characterized by 
proliferation of tissue-resident macrophages rather than monocyte recruitment[16], 
whereas macrophage accumulation in damaged muscle is supplied by infiltrating 
monocytes[1]. The relationship between macrophage origin and function is minimally 
understood, but recent studies highlight functional differences that may inform future 
design of immune-regenerative strategies. Alternatively-activated macrophages derived 
from monocytes, but not those derived from tissue-resident pools, drive differentiation of 
CD4+ T lymphocytes to Foxp3+ regulatory T lymphocytes[19], which are implicated in 
skeletal muscle regeneration[20]. Monocyte-derived macrophages may possess increased 
reparative potential compared to tissue-resident macrophages. 
 
2.3. Mononuclear phagocyte subpopulations and effector functions 
The mononuclear phagocyte system’s responses to sterile injury primarily involves 
monocytes and macrophages, both of which are comprised of highly heterogeneous 
subpopulations that exert divergent effects on injured tissue during pathogenesis and 
regeneration. Macrophage phenotype and function is described as spectrum of M1 
“inflammatory” to M2 “alternatively-activated” or “regenerative” macrophages[11]. M1 
polarization from naive macrophages in vitro is accomplished by stimulation with IFNγ, 
lipopolysaccharide, and/or TNFα[21]. M1 produce reactive oxygen species and many 
inflammatory cytokines that support necrotic tissue clearance, and growth factors such as 
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VEGF and FGF2[22-25] upon stimulation. Over-activation or excessive persistence of M1 
macrophages can contribute to tissue damage[11]. 
M2 macrophages can be further subdivided into M2a, M2b, and M2c. M2a 
polarization requires IL-4 and/or IL-13 in vitro. M2a (CD206 high) support extracellular 
matrix deposition and epithelial wound closure via high expression of arginase-1, which 
allows them to generate precursors for collagen and fibroblast stimulating factor[11].  M2b 
polarization requires immune complexes combined with toll-like receptor (TLR) or IL-1R 
ligands, whereas M2c macrophages arise via IL-10 stimulation[26]. M2b and M2c 
contribute to suppressing inflammation through secretion of IL-10. Due to macrophage 
plasticity in vivo and lack of distinguishing biomarkers, specific functions of M2a-c 
subtypes in tissue repair remain poorly understood. Nevertheless, the dominant presence 
of M2 versus M1 macrophages is associated with positive healing outcomes in numerous 
contexts[2, 6, 10, 27, 28]. 
Circulating blood monocytes are comprised of at least two functionally distinct 
subsets. Classical “inflammatory” monocytes are characteristically Ly6Chi CCR2hi 
CX3CR1lo in mice and CD14+CD16- in humans. Non-classical “anti-inflammatory: 
monocytes are Ly6Clo CCR2lo CX3CR1hi in mice and CD14loCD16+ in humans. Classical 
monocytes predominate the acute phases of injury, secrete inflammatory cytokines such as 
IL-6, iNOS, and TNFα[29], produce high levels of matrix metalloproteinases and 
cathepsins, and phagocytose debris[8], whereas non-classical monocytes predominate in 
later phase inflammation, secrete higher levels of VEGF, TGFβ, and IL-10 and lower levels 
of TNFα and IL-1β, and promote angiogenesis and matrix deposition[8, 30]. While studies 
of toxin-induced muscle injury[1], acute liver injury[31], and autoimmune disease[32] 
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show that classical monocytes are recruited from circulation and subsequently convert in 
situ into non-classical monocytes and M1 or M2 macrophages, other studies in myocardial 
infarction[8] and excisional skin injury[6] indicate that non-classical monocytes can be 
recruited directly from blood. Until recently, it was unknown whether non-classical versus 
classical monocytes give rise to distinct macrophage phenotypes. Our group is the first to 
show that non-classical monocytes recruited from blood may serve as biased progenitors 
of M2 macrophages[33]. 
 
2.4. Monocyte trafficking 
 At steady state, classical monocytes persist for approximately 19 hours before 
converting to non-classical monocytes, which persist for approximately 2 days. One study 
suggests that differentiation is unidirectional and non-classical monocytes do not give rise 
to classical monocytes[34]. Non-classical monocytes “patrol” the endothelium during 
homeostasis owing to their unique adhesion molecule signature, including low CD62L (L-
selectin)[35] and high LFA-1 (αLβ2 integrin)[36, 37]. In contrast, classical monocytes are 
sparsely present on the endothelium during homeostasis. Following tissue injury, classical 
monocytes rapidly mobilize from the spleen and/or bone marrow into blood circulation 
using the CCR2 chemokine receptor[38, 39]. Classical monocytes adhere to inflamed 
endothelium using their high expression of CD62L, Mac-1 (αMβ2 integrin), and VLA-4 
(α4β1 integrin), and then migrate up gradients of inflammatory chemokines such as MCP-
1 (CCL2) using high expression of CCR2 and CCR5 chemokine receptors[35-37, 40, 41]. 
Differential expression of chemokine receptors between monocyte subpopulations 
represents a therapeutic lever for selecting recruiting non-classical monocytes. Non-
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classical monocytes exhibit higher expression of CX3CR1[34, 42], C-X-C chemokine 
receptor type 4 (CXCR4)[27, 42], and sphingosine 1-phosphate receptor 3 (S1PR3)[6] 
compared to classical monocytes. As such, non-classical monocytes exhibit greater in vitro 
chemotaxis toward fractalkine (CX3CL1)[42], the cognate ligand of CX3CR1, and stromal 
derived factor 1-alpha (SDF-1α)[6], the ligand of CXCR4. Moreover, SDF-1α-induced 
chemotaxis of non-classical monocytes is enhanced by pretreatment with the S1PR3-
targeting small molecule FTY720. Local delivery of FTY720 selectively increases 
recruitment of non-classical monocytes to injured skin[6]. Whether the CXCR4 and 
CX3CR1 signaling axes can also be harnessed to recruit non-classical monocytes is the 
subject of the present studies. 
 
2.5. Role of mononuclear phagocytes in musculoskeletal wound healing 
2.5.1. Leukocyte-assisted angiogenesis and arteriogenesis 
Mononuclear phagocytes support vascular network growth and remodeling during 
development, homeostasis, and repair[6, 43-53]. Loss-of-function studies show that 
depletion of monocytes/macrophages inhibits arteriogenic recovery of perfusion following 
hindlimb ischemia[43], and bone-marrow deletion of CCR2, a monocyte chemokine 
receptor critical for mobilization, inhibits arteriolar remodeling in the dorsal skin window 
model[44]. Gain-of-function studies show that local delivery of CCL2, CXCL1, or 
exogenous macrophages increases the local pool of mononuclear phagocytes and enhances 
arteriogenesis and recovery of perfusion in the ischemic hindlimb[45-47]. In the context of 
angiogenesis, loss-of-function studies show that mononuclear phagocytes promote 
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vascular anastomosis[48, 49]  and vessel outgrowth[50, 54]. During vascular remodeling, 
mononuclear phagocytes are recruited to perivascular positions that may facilitate their 
pro-angiogenic and pro-arteriogenic interactions with the vasculature[30, 48, 55]. 
Perivascular monocytes and macrophages contribute paracrine signals to the remodeling 
vasculature, including secretion of growth factors such as platelet-derived growth factor 
(PDGF) and VEGF, as well as matrix-remodeling enzymes such as MMPs that create paths 
for new vessels[8, 30, 45, 48, 50, 51, 55]. Although it remains controversial whether 
monocyte/macrophage subpopulations differentially impact vascular remodeling[22, 23, 
56], literature generally associates augmented arteriogenesis and angiogenesis with 
recruitment of Ly-6Clo non-classical monocytes and M2-like macrophages[6, 10, 26, 52, 
57].   
 
2.5.2. Mononuclear phagocytes orchestrate muscle repair 
Regeneration of injured skeletal muscle is accomplished by muscle progenitor cells 
(“satellite cells”) that differentiate into muscle fibers in a process dependent on cues from 
mononuclear phagocytes[58]. Skeletal muscle possesses few tissue-resident macrophages 
and expansion of the mononuclear phagocyte pool within injured muscle requires input 
from circulating monocytes[1]. Monocytes and macrophages are recruited acutely to 
damaged muscle where they remain until completion of repair[1, 59, 60].  Monocyte 
recruitment is required for natural muscle repair; multiple studies show that depletion of 
circulating monocytes causes incomplete and fibrotic healing of skeletal muscle after toxin-
induced injury[1, 59, 60].  
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Monocyte subpopulations infiltrate injured muscle in sequential phases. Classical 
Ly6Chi monocytes accumulate early and peak in number around one day after injury, 
whereas non-classical Ly6Clo monocyte numbers rise thereafter and return to baseline upon 
completion of regeneration[1].  Monocytes may execute effector functions as bona-fide 
monocytes or as monocyte-derived macrophages[1, 24, 30, 61]. M1-like macrophages 
predominate the early phase, respond to tissue damage signals, and upregulate genes 
associated with alarmins and acute inflammatory-phase proteins[62]. M2-like 
macrophages predominate the later phase, supply insulin-like growth factor (IGF-1) 
required for muscle regeneration[63], and highly express genes governing extracellular 
matrix (ECM) proteins and ECM remodeling proteins[62]. Macrophage subpopulations 
exert differential, complementary effects on myogenic precursor cells in vitro via paracrine 
mechanisms[61]. M1-like macrophages secrete factors that stimulate myogenic precursor 
cell proliferation and migration, whereas M2-like macrophages stimulate myogenic 
differentiation and myotube fusion[1, 61]. Taken together, these results suggest that 
coordination between subpopulations of monocytes/macrophage orchestrates skeletal 
muscle repair.   
 
2.5.3. Mononuclear phagocytes may regulate rotator cuff muscle pathogenesis 
Evidence from RCT and chronic muscle pathologies suggests that inflammation, 
particularly mononuclear phagocyte (MP) infiltration, contributes to muscle degeneration. 
Pro-inflammatory cytokines such as TNFα and IL-6 stimulate apoptosis of myocytes and 
catabolism of intramyocellular proteins[64, 65], thus causing muscle atrophy in cancer 
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cachexia and autoimmune disorders. Classical “pro-inflammatory” subpopulations of 
mononuclear phagocytes secrete more pro-inflammatory cytokines compared to non-
classical alternatively-activated subpopulations[8, 11, 22-24], suggesting that 
intramuscular infiltration of classical subtypes may promote chronic muscle degeneration. 
Indeed, in the mdx mouse model of Duchenne muscular dystrophy, chronic muscle 
degeneration is in part caused by the classical pro-inflammatory Ly6Chi subset of 
circulating monocytes (MO)[66]. Human and rodent muscles undergoing fatty 
degeneration after RCT show dramatic co-localization of fat-rich regions with 
macrophages (MF) that contain intracellular lipid droplets[67, 68]. Rotator cuff muscle 
degeneration is exacerbated by administration of lysophosphatidic acid, whereby MF 
accumulation and TNFα expression are increased[69]. Taken together, these studies 





3. MONOCYTE RECRUITMENT AND VASCULARIZATION OF 
INJURED SKIN IN RESPONSE TO MANIPULATION OF 
CHEMOKINE SIGNALS USING BIOSYNTHETIC MATERIALS1 
3.1. Abstract 
3.2. Introduction 
Anti-inflammatory and regenerative effects of non-classical monocytes 
(Ly6CloCX3CR1hi) and M2-like macrophages (CD206+) have been described in numerous 
and diverse contexts including myocardial infarction[8], vascular network expansion[6, 26, 
52, 57], musculoskeletal injury[1], dermal wounds[7], central and peripheral nervous 
system injury[2-5, 70-72], and integration of cell, tissue, and biomaterial constructs[10, 73, 
74]. Approaches to promote regenerative responses via mononuclear phagocytes can 
include polarizing macrophages towards an M2-like phenotype with cytokines (e.g. IL-4, 
IL-10)[2, 75], stimulating proliferation of tissue-resident M2-like macrophages, or 
recruiting circulating non-classical monocytes which differentiate preferentially into M2-
like macrophages[33]. The present study evaluates novel biomaterial-based strategies to 
selectively recruit non-classical monocytes by leveraging their high surface expression of 
the chemokine receptors CX3CR1 and CXCR4[34, 76, 77].  
CX3CR1 is the cognate receptor of fractalkine (FKN; CX3CL1), a 373 amino-acid 
cytokine with a small (8.6 kD) soluble chemotactic domain that can dissociate and signal 
                                                
1 Adapted from: J.R. Krieger, M.E. Ogle, J. McFaline-Figueroa, C.E. Segar, J.S. Temenoff, 
E.A. Botchwey, Spatially localized recruitment of anti-inflammatory monocytes by SDF-
1alpha-releasing hydrogels enhances microvascular network remodeling, Biomaterials 77 
(2016) 280-90. Reprinted by permission of Elsevier. 
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through CX3CR1[78]. Elevated FKN and CX3CR1+ cell recruitment[70] are associated 
with improved healing after brain injury in rodents[79, 80] and humans[81, 82]. To target 
the FKN-CX3CR1 axis via engineered enrichment of FKN within injured tissue, we 
designed aptamer-functionalized hydrogels (“aptagels”) that catch and release endogenous 
FKN. Aptamers are single-stranded DNA or RNA oligomers that specifically bind 
biomolecular targets via non-covalent interactions[83]. Aptamers can be easily modified 
to tune binding kinetics, enable immobilization onto a surface, and mitigate enzyme-
mediated degradation[84-88]. Aptamers are versatile tools used in the diagnosis and 
treatment of diseases, and employed in the identification and purification of targets[89-93]. 
Multiple clinical trials of aptamer-based therapeutics are underway and demonstrate 
promising safety profiles[94-96]. In this study, FKN-aptamer binding kinetics with FKN 
variants are assessed and aptagels are fabricated by immobilizing modified aptamers to 
poly(ethylene glycol) diacrylate (PEGDA). Aptagels are tested for their ability to catch and 
release FKN in vitro and recruit non-classical monocytes and M2-like macrophages to 
injured tissue in vivo. 
Delivery of exogenous FKN has been attempted previously to modulate 
inflammation[79, 97-99]. However, delivery of exogenous proteins poses problems of 
short half-life[100-103], suboptimal efficacy[104], risk of immune reactions[105-107], 
batch-to-batch variabilities, and high costs. Enrichment of endogenous FKN may 
circumvent these critical hurdles to clinical translation by concentrating therapeutic 
proteins at the injury site, exploiting the efficacy of endogenous signaling pathways, not 
introducing anomalous structures or glycosylation patterns; and mitigating cost, 
manufacturing and regulatory hurdles. 
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 CXCR4 is the cognate receptor of stromal derived factor-1α (SDF-1α; CXCL12), 
a CXC family chemokine that is increased in tissue after injury and mediates the 
recruitment of innate immune cells that directly and indirectly participate in the growth of 
microvascular networks. CXCR4 is highly expressed on immune cells and several known 
adult stem/progenitor cell sources, including mesenchymal stem cells, hematopoietic 
stem cells, and endothelial progenitor cells among others[108-110]. Previous reports 
suggest a prominent role for the cell surface receptor CXCR4 in regulating monocyte 
retention and tissue distribution following tissue damage[30, 111, 112]. We have also 
observed that non-classical monocytes in particular may be functionally distinguished 
from classical monocytes by their increased CXCR4-mediated chemotaxis and that 
selective recruitment of non-classical monocytes along peri-implant arterioles promotes 
growth and maturation of microvessel networks in both skin and muscle injury models[6, 
53].     
In this study, we investigate how localized presentation of SDF-1α from engineered 
hydrogels impacts the recruitment and strategic distribution of circulating monocytes 
populations during sterile inflammatory wound healing and vascular remodeling. We have 
shown previously that particular derivatives of the glycosaminoglycan (GAG) heparin can 
protect growth factors such as BMP-2 from denaturing conditions, and that heparin-based 
biomaterials enable sustained presentation of biomolecular cargo and decrease the amount 
of growth factor necessary to achieve the same physiological response as bolus 
delivery[113-115]. Heparin enhances the loading of growth factor cargo into biomaterials 
and increased heparin content in the material can enhance the amount of growth factor 
released, likely by preventing denaturation of the growth factor within the carrier[115]. 
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Thus, heparin derivatives are an excellent choice for sustained delivery of heparin-binding 
proteins such as SDF-1α[116]. To enable safe in vivo use of heparin-based biomaterials in 
present and future studies, we employed a desulfated heparin formulation that exhibits very 
low anticoagulant activity and extends the half-life of growth factors in solution and in 
delivery systems[114, 115, 117-122]. In this study, PEGDA hydrogels functionalized with 
N-desulfated heparin (Hep-N) are loaded with SDF-1α in the presence of albumin as a 
stabilizing factor[123, 124].  
We utilize the murine dorsal skinfold window chamber, a model of excisional skin 
injury, to test longitudinally the effects of FKN aptagels and SDF-1α-releasing heparin 
hydrogels on recruitment of non-classical monocytes and associated angiogenesis in vivo. 
Multiple modes of analysis, including intra-vital microscopy, flow cytometry, and whole-
mount immunostaining of dorsal skin tissues are used.      
 
3.3. Results 
3.3.1. Fractalkine aptamers exhibit desirable binding kinetics with mouse 
fractalkine 
The present study utilizes the FKN-aptamer sequence (FKN-S2) discovered by 
Waybrant et al[125] that was selected against human FKN (hFKN) through Selective 
Enrichment of Ligands via EXponential enrichment (SELEX). Mouse FKN (mFKN) 
possesses 78% homology to hFKN. Binding activity and kinetics of FKN- and SCR-
aptamers to hFKN and mFKN were measured via surface plasmon resonance (SPR). In 
initial screening studies, FKN-aptamers bound to the mFKN surface with a ten-fold weaker 
 17 
binding response compared to the hFKN surface, as expected (Figure 1a,b). No interaction 
was observed with the SCR-aptamers or the MSA surface for either aptamer (Figure 1a-
c). Kinetic measurement revealed that the FKN-aptamers bound mFKN with an affinity 
(Kd = 1220 nM) that is approximately four-fold weaker than that observed for the hFKN 
(Kd = 340 nM) (Figure 2c). Interestingly, the observed difference in affinity is almost 
entirely accounted for in the dissociation kinetics as the mFKN interaction demonstrates 
marginally faster association kinetics but four-fold faster dissociation kinetics (kon = 1.34 
x 105 M-1s-1, koff = 0.163 s-1) when compared to the hFKN complex (kon = 1.25 x 105 M-1s-
1, koff = 0.043 s-1) (Figure 2c). These results indicate that the FKN-aptamer sequence is an 
appropriate candidate for attempting endogenous enrichment of mFKN. 
 
Figure 1. Preliminary binding analysis via surface plasmon resonance. Sensor chip 
was immobilized with a high amount of (A) mouse FKN (mFKN) or (B) human FKN 
(hFKN) followed by binding and release of either FKN-aptamers (blue) or SCR-aptamers 
(orange). (C) Sensor chip immobilized with mouse serum albumin demonstrated negligible 




Figure 2. Surface plasmon resonance to study the kinetics of aptamer-FKN 
interactions. Response curve of a range of concentrations of FKN-aptamer flowed across 
immobilized (A) hFKN and (B) mFKN. (C) Binding kinetics demonstrated equivalent kon 
rates but mFKN displayed faster koff rates. 
 
3.3.2. Acrydite-modified aptamers can be integrated with PEGDA to form 
aptagels  
To conjugate the FKN- or SCR-aptamers with a PEGDA hydrogel backbone, a 
phosphoramidite group, Acrydite, was added to the 5’ end of the aptamers and was 
expected to minimally affect kinetics[126]. As aptagel formulation precluded SPR 
assessment of potential perturbation of binding kinetics, functional testing was performed 
after aptagel synthesis. The Acrydite-modified aptamers were conjugated to PEGDA via 
free-radical polymerization initiated by APS and catalyzed by TEMED (Figure 3a). Soft 
and translucent hydrogels (aptagels) formed at a concentration of 5% PEGDA in a 0.5-mm 
thick glass mold and were punched out with a 2-mm biopsy (Figure 3b). Successful 
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covalent integration of Acrydite-modified aptamers with PEGDA was confirmed by 
incubating the aptagels with fluorescently-tagged complementary sequence (fCS) and 
comparing fluorescence to aptagels fabricated using unmodified aptamers or no aptamers 
(Figure 3c). A stark difference in fluorescence was appreciated in the Acrydite-modified 
aptagel group compared to either controls. Alternative chemistries were tested for potential 
application of endogenous enrichment to various scenarios in vivo. Amino-modified 
aptamers also successfully conjugated to N-hydroxysuccinimide (NHS) activated agarose 
beads, as determined by fCS. Fluorescence intensity correlated with the amount of aptamer 
conjugated (Figure 3d). 
 
Figure 3. Chemistry and synthesis of aptagels. (A) Schematic of aptamer conjugation 
chemistry. (B) Bulk aptamer-functionalized PEGDA hydrogels (aptagels). (C) Staining 
with 6-carboxyfluorescein-labelled complementary sequence. (D) Alternate chemistry 
(NH2 modified aptamers with NHS-activated agarose beads) for generating “aptabeads”. 
The amount of aptamer conjugated correlated with the level of fluorescence staining. 
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3.3.3. Aptagels enrich and passively release fractalkine for at least 1 week in vitro 
Aptagel functionality was assessed in vitro by measuring sequestration (indirectly, 
Day 0) and release (directly, Day 1 and onwards) of FKN after 24 h of incubation with 
either FKN- or SCR-aptagels (Figure 4a). Preliminary studies with rat FKN (rFKN) 
demonstrated that FKN-aptagels attract at least 40% of rFKN from high concentration 
incubations (1 µg/mL) (Figure 5a). Studies with aptabeads demonstrated immediate 
release of rFKN with the addition of complementary sequence (CS; 1 nmol) and equivalent 
passive release over 24 hours with the non-homologous CS, corroborating the fast koff rates 
observed with SPR (Figure 5b). At least two washes were necessary to exclude non-
specifically bound FKN from passive release data (Figure 5c). Because endogenous FKN 
concentrations range from hundreds of picograms to nanograms per milliliter[127], formal 
studies with mFKN were then performed using a lower concentration (50 ng/mL). 
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Figure 4. Aptagel functionality in vitro. (A) Schematic of methodology. (B) Amount of 
mFKN remaining in bath surrounding aptagels (n = 3; P < 0.01). (C) Concentration of 
mFKN in aptagels compared to bath. (D) Calculated ‘bound’ mFKN and Day 1 release (n 
= 3; ***P < 0.001) (E) Amount of mFKN released daily from aptagels. (n = 4; ****P < 
0.0001 compared to Day 6 FKN-aptagel release) (F) Cumulative mFKN release from FKN-
aptagel (n = 4; P at least < 0.001 for each comparison) (F) Functionality was assessed after 
7 days of testing. All graphs depict mean and standard deviation. One-way and repeated 




Day 0 samples demonstrated reduced mFKN levels in the bath surrounding FKN-
aptagels, indicating sequestration of mFKN onto the aptagels (Figure 4b). No change was 
observed around SCR-aptagels (Figure 4b). Pre-treatment of the aptagels with 25 units of 
DNAse dampened FKN binding, indicating aptamer-protein interactions (Figure 4b-d). 
The FKN- and SCR-aptagels sequestered ~30% (40.8 ng ± 4.2 ng) and <0.1% (2.2 ± 2.2 
ng) respectively from the initial amount of mFKN in the baths (138.1 ± 3.7 ng) (Figure 
4b,d). Relative to the unbound FKN, the FKN-aptagels were 67X concentrated while the 
SCR-aptagels 2.6X concentrated (Figure 4c). After washes and transferring the aptagels 
to fresh baths, FKN-aptagels passively released 30% (12.4 ± 4.8 ng) of the sequestered 
amount over 24 h (Figure 4d). These methods were iterated daily, and 72.5% of mFKN 
was passively released over seven days (Figure 4e,f). After this period, FKN-aptagels were 
still able to sequester 28% of FKN from a fresh incubation, indicating near-full 
functionality (Figure 4g). Increasing BSA concentration five-fold reduced mFKN binding 
to FKN-aptagels (Figure 5d,e), still greater than SCR-aptagels, and demonstrated 
sustained release for at least 2 days (Figure 5f). These results demonstrate that FKN-
aptagels can catch mFKN from the environment and passively release it while SCR-
aptagels have no specific effect on mFKN. 
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Figure 5. Supplementary analysis of aptagel functionality in vitro. (A) FKN-aptagels 
demonstrated significant binding and release of rFKN (n = 3, ****P < 0.0001). (B) 
Incubation of homologous CS with FKN-aptabeads resulted in release of rFKN while non-
homologous CS failed to evoke the response. A wash with wash media (1% BSA and PBS) 
resulted in the release of rFKN that previously failed to release, indicating fast off-kinetics 
(n = 3). (C) After obtaining the “unbound” sample, three washes were sufficient to remove 
non-specifically bound FKN (n = 3). (D) FKN-aptagels captured mFKN from media with 
elevated (5%) BSA (n = 3, **P < 0.01). (E) FKN-aptagels incubated in 5% BSA bound 
less mFKN than those incubated in 1% BSA (n = 3, **P < 0.01). (F) FKN-aptagels 
incubated in 5% BSA released mFKN for at least 2 days (n = 3). 
 
3.3.4. Aptagels enrich endogenous fractalkine and M2-like macrophages in vivo 
To assess the ability of aptagels to enrich anti-inflammatory subpopulations of 
monocytes and macrophages, aptagels were implanted in the mouse dorsal skin window, a 
model of excisional skin injury. One week after injury and gel implantation, enrichment of 
endogenous FKN within the hydrogel was quantified by ELISA, and immune cell 
infiltration was analyzed via flow cytometry, t-Distributed Stochastic Neighbor 
Embedding (t-SNE) high-dimensional analysis, and intra-vital imaging (Figure 6a). FKN-
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aptagels contained 3.7-fold more endogenous FKN than SCR-aptagels (Figure 6g), 
indicating that FKN-aptagels successfully enrich FKN in vivo. To assess spatial 
localization of effects on immune cell infiltration, biopsies were collected from tissue 
underneath the gel (“near” region) and from tissue at the opposite side of the window (“far” 
region) (Figure 6a). FKN-aptagels increased the number of CD206+ macrophages in the 
near tissue 3.8-fold compared to far tissue and 13.2-fold compared to tissue near the SCR-
aptagels (Figure 6c). Neither FKN-aptagels nor SCR-aptagels affected total macrophage 
count with statistical significance (Figure 7a). FKN-aptagels increased and SCR-aptagels 
decreased the proportion of macrophages expressing the CD206+ alternatively-activated, 
M2-like phenotype in near tissue compared to far tissue (Figure 6d). FKN-aptagels 
increased the number of non-classical monocytes in near tissue 3.0-fold compared to far 
tissue and 6.4-fold compared to tissue near the SCR-aptagels (Figure 6e). Neither SCR- 
nor FKN-aptagels significantly affected the total number of monocytes or the frequency of 
non-classical monocytes out of total monocytes compared to the far region (Figure 7b-d). 
No significant differences were observed in neutrophil populations at day 7 either (Figure 
7e). These results indicate that FKN-aptagels dramatically enhance accumulation of non-
classical monocytes and M2-like macrophages in injured tissue near the implant. 
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Figure 6. Aptagel immune modulation in vivo. (A) Experimental design. (B) Amount of 
mFKN released from explanted aptagels over 24 hours (n = 3, **P < 0.01, t-test). Flow 
cytometry analysis of (C) CD206+ M2-like macrophage count, (D) polarization of 
macrophages towards expression of CD206, and (E) Ly6Clo non-classical monocyte count 
(n = 4, *P < 0.05, **P < 0.01, two-way ANOVA). (F) tSNE analysis applied to (F) 
CD45+CD11b+ cells collected from both tissue regions in both aptagel groups, (G) 
CD45+CD11b+ cells from near tissue regions, and (H) CD45+CD11b+ cells from tissue in 
FKN-aptagel group. (I) t-SNE map color coded per CD206 expression in near tissue region 
of SCR-aptagel (left) or FKN-aptagel (right) groups. 
 
 
Figure 7. Supplementary analysis of aptagel immune modulation in vivo.  Flow 
cytometry analysis of (A) total macrophage count, (B) total monocyte count, (C) Ly6Chi 
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classical monocyte count, (D) frequency of monocytes out of total cells, and (D) frequency 
of neutrophils out of total cells (n = 4). (F) tSNE analysis applied to CD45+CD11b+ cells 
collected from dorsal tissue surrounding SCR or FKN aptagels (both far and near regions). 
 
3.3.5. CX3CR1+ cells demonstrate decreased motility by day 7 around FKN-
aptagels 
To assess whether chemotaxis of monocytes and macrophages towards aptagels 
persisted to day 7, time-lapse videos of CX3CR1+ cell migration were acquired by confocal 
intra-vital microscopy in CX3CR1gfp/+ transgenic mice (Error! Reference source not 
found.a,b), in which monocytes and macrophages are visualized by GFP expression[6, 34, 
128]. Cell migrations paths (Error! Reference source not found.c,d) and displacement 
vectors (Error! Reference source not found.e,f) were rendered and CX3CR1+ cell migration 
in the tissue surrounding FKN-aptagels exhibited decreased speed, increased path length, 
and decreased displacement length compared to SCR-aptagels (Figure 8g-i). These data 
demonstrate that by day 7, directional motility of CX3CR1+ cells in the tissue around FKN-




Figure 8. Time-lapse imaging of CX3CR1+ cell migration near aptagel edges via 
confocal intra-vital microscopy in CX3CR1gfp/+ mice. (A-B) 3D projection of CX3CR1+ 
cell distribution. (C-D) 4D rendering of cell migration paths. (E-F) Displacement vectors 
of CX3CR1+ cell migration. Metrics of cell migration dynamics include (A) displacement 
length, (B) path straightness, (C) mean speed, and (D) path length. All graphs depict mean 
and standard deviation. (n = 300 cells across 3 animals per group, *P < 0.05, ****P < 
0.0001, t-test). 
 
3.3.6. aHep-N-SDF hydrogels sustain release of bioactive SDF-1a in vitro 
A selectively desulfated heparin PEG-DA hydrogel (Hep-N) was engineered to 









































































novel strategy to produce a localized in vivo gradient of SDF-1α[113-115, 117, 121]. 
Fabrication and composition of heparin-containing hydrogels is illustrated in Figure 9a. 
SDF-1α release from Hep-N gels incorporating albumin was superior to release from either 
unmodified PEG-DA, Hep-N-PEG-DA, or albumin-PEG-DA gels (Figure 10); therefore, 
in subsequent experiments, albumin was included in the Hep-N-PEG-DA hydrogels (aHep-
N) to improve release of SDF-1α. The albumin may help stabilize the protein from 
denaturation within the gel and since albumin is also negatively charged at neutral pH, may 
reduce growth factor binding to the gel and thus promote release[123, 124].  The albumin-
containing, N-desulfated heparin-based hydrogels (aHep-N) chosen for this study released 
9.8 ± 0.1% of the loaded SDF-1α by 5h, 19.2 ± 0.1% by 24h, 23.1 ± 0.1% by day 3, and 
23.8 ± 0.0% by day 7 in vitro (Figure 9b). Chemotaxis of primary murine bone marrow 
cells toward hydrogel conditioned media was analyzed to test the bioactivity of SDF-1α 
released from the hydrogels. Media conditioned for 24h with aHep-N-SDF gels induced a 
statistically significant increase in directional chemotaxis (27.22 ± 9.5%) compared to 
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release media from the same gels with no SDF-1α (aHep-N), indicating that SDF-1α 
bioactivity is retained after release from aHep-N hydrogels (Figure 9c).  
 
Figure 9. aHep-N hydrogel provides sustained release of bioactive SDF-1α. (A) 
Hydrogels were fabricated by thermal cross-linking of N-desulfated heparin 
methacrylamide and PEG-DA. Hydrogel formulations used in this study were: unloaded 
(Hep-N) internal controls, albumin loaded (aHep-N), or SDF-1α and albumin loaded (aHep-
N-SDF). (B) SDF-1α release from aHep-N-SDF hydrogels is sustained over 3 days in vitro 
(n=3, mean ± SD) and (C) stimulates chemotaxis of mouse bone marrow cells in vitro 




Figure 10. Effect of albumin on SDF-1α release. Cumulative release of SDF-1α from 
hydrogels composed of PEG-DA only (PEG, blue line), PEG-DA with albumin (aPEG, 
green line), PEG-DA with N-desulfated heparin methacrylamide (Hep-N, yellow line), and 
PEG-DA with both N-desulfated heparin methacrylamide and albumin (aHep-N, red line). 
(n=4, mean ± SD). 
 
3.3.7. aHep-N-SDF hydrogels locally recruit marrow derived cells in vivo 
The murine dorsal skinfold window chamber (“backpack”) model enables 
longitudinal spatiotemporal intravital imaging of host responses to biomaterial implants 
including remodeling of vessel networks and coupled innate immune response[6, 53]. To 
evaluate the in vivo recruitment of circulating cells to the gels, we generated mouse 
chimeras whose bone marrow-derived hematopoietic lineage cells express a constitutive 
enhanced green fluorescent protein (EGFP) transgene. Chimeric mice fitted with dorsal 
skinfold windows permit the tracking of cells originating from the bone marrow and 
arriving at the injury niche. The experimental design was internally controlled to evaluate 
a localized biological response around the gel by implanting one aHep-N-SDF 
(“experimental”) gel and one Hep-N (“internal control”) hydrogel into opposite sides of the 
same window (less than 8mm separation between center of each gel) (Figure 11a). Whole 
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mount immunofluorescence microscopy analysis of dorsal skinfold tissue 2 days after 
surgical tissue disruption and hydrogel implantation showed that the aHep-N-SDF hydrogel 
appeared to recruit more bone marrow-derived (EGFP+) circulating cells than internal 
control hydrogels in the same dorsal skinfold window chamber (Figure 11b). Moreover, 
the spatial distribution of recruited bone marrow-derived cells was localized to the SDF-
1α implant niche, as indicated by higher trend in EGFP fluorescence underneath the SDF-
1α-releasing gels compared to paired internal controls in all 3 animals (p=0.1; Figure 11c). 
 
Figure 11. SDF-1α recruits bone marrow-derived cells to the hydrogel implant niche. 
(A) Chimeric mice were generated as illustrated by irradiation and bone marrow 
transplantation from an EGFP transgenic mouse. (B) Brightfield tiled image of dorsal 
skinfold window chamber on day 0 with location of aHep-N-SDF and internal control gels. 
(C) Rendering of Z-stacked tile scans acquired via confocal laser scanning microscopy 
show that more EGFP+ bone marrow-derived cells (green) are recruited to the tissue 
beneath aHep-N-SDF hydrogels compared to Hep-N internal control and recruitment is 
highly localized. Vessels are counterstained with αSMA (red). (D) Percent area under the 
gel positive for GFP. Lines connect paired analysis of internal control and experimental 
gels in each animal (p=0.1 by paired t-test, n=3; scale bar = 1mm). 
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3.3.8. aHep-N-SDF hydrogels enhance local recruitment of non-classical 
monocytes 
To further evaluate the identity and localization of recruited cells, wildtype 
C57/BL6 mice were implanted with one experimental (aHep-N or aHep-N-SDF) gel and one 
internal control unloaded gel (Hep-N) as described above (Figure 12a). To examine the 
phenotypes of recruited cells in the tissue surrounding each implant, dorsal tissue was 
harvested and bisected along the midline separating the two hydrogels (Figure 12a). The 
proportion of CD11b+ cells out of total cells in the digested dorsal tissue was not different 
between groups (Figure 12b); however, hydrogels releasing SDF-1α significantly increased 
the tissue recruitment of non-classical monocytes (CD11b+SSCloLy-6Clo) compared to 
aHep-N animals (Figure 12c). Local infiltration of classical monocytes (CD11b+SSClowLy-
6Chigh) was not significantly different between unloaded and SDF-1α-loaded aHep-N gels 
(Figure 12d). The ratio of non-classical to classical monocytes was significantly higher in 
the tissue surrounding the SDF-1α releasing hydrogels compared to both the Hep-N internal 
control and the aHep-N experimental control hydrogels (Figure 12e). To gain mechanistic 
insight into the preferential recruitment of non-classical monocytes by SDF-1α, we 
analyzed the cell surface expression of the SDF-1α cognate receptor, CXCR4. Bone 
marrow-derived non-classical monocytes have higher surface expression of CXCR4 
compared to classical monocytes (Figure 12f) These data suggest that the SDF-1α releasing 
hydrogel preferentially attracts the pro-regenerative non-classical subset of monocytes to 
the tissue surrounding the gel, which is in accordance with our previous work showing that 
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non-classical monocytes migrate toward SDF-1α significantly more than classical 
monocytes[6]. 
 
Figure 12. Localized recruitment of anti-inflammatory monocytes to the tissue 
surrounding the aHep-N-SDF hydrogel. (A) Tissue was bisected between the internal 
control (Hep-N, white) and the experimental (aHep-N or aHep-N–SDF, black) gels, digested 
with collagenase, and analyzed by flow cytometry. (B) The proportion of CD11b+ cells in 
the implant niche is not significantly different between groups. (C) aHep-N-SDF hydrogels 
induce a significant increase in the recruitment of non-classical monocytes, but not 
classical monocytes (D) to the peri-hydrogel tissue. (E) The ratio of non-classical to 
classical monocytes in the tissue surrounding aHep-NSDF hydrogels is higher than aHep-N 
experimental control and Hep-N internal control. (F) Surface expression of the SDF-1α 
cognate receptor CXCR4 is higher on the surface of non-classical compared to classical 
monocytes.  (#, *p<0.05: two-way ANOVA with repeated measures and Bonferonni test 




































3.3.9. Early arteriolar vascular expansion correlates with non-classical monocyte 
recruitment 
Previous reports suggest that perivascular positioning of monocytes and 
macrophages promotes vascular remodeling[6, 48, 55]; therefore, we utilized intravital 
confocal laser microscopy analysis of post-capillary venules to examine the infiltration and 
positioning of CX3CR1-EGFP+ monocytes (Figure 13a,b, green) with respect to vessels 
(Figure 13a,b, red) in the peri-implant region. Images were further processed with Imaris 
software to generate 3D surface renderings and visualize cell proximity to vessels; a 3D 
distance heat map was overlayed on the cells (Figure 13c,d). Significantly more CX3CR1+ 
cells were observed in regions of interest around the aHep-N-SDF hydrogels on day 1 after 
dorsal window chamber placement (Figure 13e; 68 ± 17 cells (Hep-N) vs. 127 ± 88 (aHep-
N-SDF) in 0.49mm2 area; n=3 mice). Early recruitment of CX3CR1high non-classical 
monocytes was also observed (10 ± 4 cells (Hep-N) vs. 22 ± 10 (aHep-N-SDF); n=3 mice) 




Figure 13. Monocyte recruitment correlates with early arteriolar remodeling. (A, B) 
Representative intravital imaging adjacent to each gel 1 day after surgery in CX3CR1-
eGFP mice. (C, D) Color-coded map of 3D distance of CX3CR1+ cells from the surface 
of vessels rendered in Imaris software shows increased distribution of monocytes near 
vessels (perfused lectin, grey) near the aHep
-N
-SDF gel (scale bar = 100µm, color scale: 
0.00 to 0.275mm distance to vessel). (E) SDF-1α release increases perivascular CX3CR1+ 
cells (*p<0.05, paired ratio t-test, n=3, mean ± SEM). (F) The percent change in arteriolar 
diameter from day 0 is not significantly changed on day 3 (Lines connect paired analysis 
of internal control and experimental gels in each animal); however, (G) the change from 
internal control significantly increased (#p<0.05, one-tailed t-test, n=3-4, mean ± SEM). 
(H) The change in vessel diameter is highly correlated to the balance of non-classiacal and 











Longitudinal intravital brightfield microscopy analysis of hydrogel-treated dorsal 
tissue at days 0 and 3 does not show significant changes between groups in the diameter of 
peri-implant arterioles with an initial diameter less than 40µm (Figure 13f); however the 
change in arteriolar diameter in aHep-N-SDF animals relative to the internal control was 
Ly6Clo / Ly6Chi ratio
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significantly higher than aHep-N relative to its internal control (Figure 13g, n=3-4 mice per 
group, #p<0.05, paired t-test). Linear regression analysis of paired immunophenotyping 
(by flow cytometry) and vessel measurements (by intravital imaging) indicates that 
arteriolar diameter enlargement positively correlates with non-classical:classical monocyte 
ratio in peri-implant tissue for both the SDF-1α- loaded and unloaded controls (Figure 
13h). SDF-1α increased the slope of the regression line compared to unloaded gels 
suggesting that SDF-1α may amplify the positive effects of non-classical monocyte 
recruitment with respect to arteriolar diameter increase (Figure 13h). 
 
3.3.10. aHep-N-SDF hydrogels sustain local arteriolar expansion and 
microvascular network growth 
SDF-1α release maintained peri-implant arteriolar structural enlargement at day 7 
(Figure 14a). All animals exhibited a positive arteriolar enlargement response to SDF-1α 
release from aHep-N-SDF gels compared to internal control while aHep-N gels did not differ 
from internal controls (Figure 14b). Accordingly, the change in arteriolar diameter in 
aHep-N-SDF relative to the internal control was significantly higher than aHep-N relative to 
its internal control (Figure 14c; -2.45% ± 10.55% (aHep-N) vs. 24.10% ± 6.43% (aHep-N-
SDF); n=3-5). We hypothesized that the sustained pro-arteriogenic response may be 
supported by the persistence of recruited non-classical monocytes through their 
differentiation into macrophages, particularly of the M2 phenotype associated with 
regeneration[6, 71]. CD206+ M2-like macrophages were identified in a peri-arteriolar 
niche location (Figure 14d), a phenomenon previously associated with 
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arteriogenesis[129]. SDF-1 delivery increased the frequency of CD206+ macrophages 




-SDF hydrogels sustain inflammatory arteriolar remodeling. (A) 
Dorsal skinfold tissue treated with aHep
-N
-SDF hydrogels increases vessel caliber 
(arrowheads) and tortuosity (asterisks) by day 7 (Scale bar 2mm). (B) All animals display 
significantly increased arteriolar diameter near aHep
-N
-SDF hydrogels compared to 
internal controls. (*p<0.05 by two-way ANOVA with repeated measures and Bonferonni 
test for multiple comparisons, n=3-5 from 2 independent experiments, lines connect paired 
analysis of internal control and experimental gels in each animal). (C) The relative increase 
























like macrophages were identified in the tissue beneath aHep
-N
-SDF hydrogels and 
associated internal controls (red, CD31 and αSMA; blue, CD68; green, CD206; scale bar 
= 50µm). M2-like macrophages were localized in a peri-arteriolar niche (arrowheads). 
Lower panels: internal control Hep
-N
 gels. (E) Frequency of CD206+ macrophages within 
the macrophage pool (*p<0.05, t-test, n=5-11 regions across 2-3 mice per group, mean ± 
SEM). 
 
In addition to rapid changes in perfusion that can be accommodated by arteriogenic 
changes in local vasculature, angiogenic microvascular network growth is another 
hallmark of regenerative vascular remodeling. Analysis of network length in brightfield 
intravital microscopy was unable to detect differences in vessel length density between 
groups (Figure 15a,b) perhaps due to the resolution limit of this technique (approximately 
20-25µm). However, whole mount CD31 immunostaining of perfusion-fixed, explanted 
dorsal skin enabled visualization of capillary-level microcirculation undetectable by 
brightfield imaging (Figure 15c,d,e,f). Tissue surrounding internal control hydrogels 
appeared to be more optically opaque in brightfield imaging, possibly indicating the 
formation of granulation tissue that may obscure visualization of microvessels. SDF-1α 
delivery from aHep-N-SDF hydrogels significantly increased the density of CD31+ vessels 
near the implant compared to internal control less than 8mm away in the window chamber 
at day 7 (Figure 15g). These data support the idea of highly localized regenerative capacity 





-SDF hydrogels enhance inflammatory microvascular network 
growth. (A, B) Intravital brightfield microscopy and (C, D) CD31
+
 whole mount 
immunofluorescence imaging of microvasculature surrounding gels. (E-F) Enlarged view 
of microvascular network in the region of a secondary-to-tertiary venular branch point near 
the hydrogel (scale bar = 500µm) (G) Analysis of 4mm-diameter circular ROI 
circumscribing each gel region (shown in Figure S4) indicates increased density of 
microvessels near aHep
-N
-SDF hydrogels compared to internal control in all animals 
(*p<0.05 by paired t-test, n=3, lines connect paired analysis of internal control and 
experimental gels in each animal). 
 
3.4. Discussion 
3.4.1. Fractalkine aptagels 
Aptagel-mediated enrichment of endogenous FKN avoids several major 
disadvantages of exogenous protein delivery, including their short half-lives in vivo, their 
suboptimal efficacy, the risk of immunogenic responses, batch variabilities and high costs 
in synthesis or purification[79, 80, 97-99]. Exogenous proteins exhibit short half-lives[100-
103] and reduced potency[104] due to a lack of post-translational modifications (PTMs), 
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molecular instability and non-native glycosylation patterns.  This is exacerbated by 
destabilizing insults during manufacturing, purification, storage, and delivery of exogenous 
proteins. PTMs significantly affect chemokine activity in vitro and in vivo. Engineering 
patterns of glycosylation that mimic endogenous proteins may ameliorate protein 
instability, but glycosylation biology is intrinsically complex and the glycoengineering 
process is technically challenging[104]. Circulation and clearance[102, 103] also reduce 
half-lives of small proteins, and achieving therapeutic pharmacodynamics may require 
multiple doses or sustained-release of otherwise fragile exogenous proteins. Immunogenic 
reactions are initiated by antibodies that react to small structural differences between 
exogenous and endogenous proteins[105, 106]. These anomalies in exogenous proteins 
arise primarily from variations in peptide sequence and glycosylation patterns, as well as 
detrimental effects of the manufacturing and storage process. The antibodies hamper 
efficacy, pharmacokinetics and pharmacodynamics, and risk the development of 
autoimmunity and systemic immune effects such as anaphylaxis and cytokine release 
syndrome[107].  Clinical translation of therapeutic proteins is further delayed because pre-
clinical models poorly predict clinically relevant immunogenicity[107]. Lastly, 
synthesizing or purifying exogenous proteins is expensive, and managing batch-to-batch 
variability requires solutions in the manufacturing and quality control process that increase 
cost of production. As discussed earlier, enriching endogenous proteins can ameliorate 
these problems by 1) concentrating target proteins in the injury site; 2) exploiting the 
efficacy of PTMs and endogenous signaling pathways; 3) avoiding the introduction of 
anomalous structures or glycosylation patterns; 4) mitigating cost, manufacturing, and 
regulatory hurdles to clinical translation. 
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Accumulation of non-classical monocytes and M2-like macrophages within injured 
tissue is associated with augmented repair and enhanced implant integration[6-8, 27, 57, 
70, 130-136]. A novel strategy to stimulate pro-regenerative inflammation is to enhance 
the recruitment of circulating non-classical monocytes, which are biased progenitors of 
M2-like macrophages[33]. Elevation of FKN and CX3CR1 is associated with better 
healing in dermal wound injuries[7, 131, 137]. Toward this end, the present study leverages 
non-classical monocytes’ relatively high surface expression of CX3CR1, the cognate 
receptor of the chemokine FKN. To target the FKN-CX3CR1 axis, we synthesized 
implantable aptamer-functionalized hydrogels that catch and release FKN protein. Results 
in vitro show that mFKN binds to FKN-aptamers but rapidly dissociates, and that aptagels 
catch and passively release FKN for at least one week. Aptagel implantation in a murine 
excisional skin wound enriches endogenous FKN within the gel matrix and increases 
accumulation of non-classical monocytes and M2-like macrophages in the injured tissue 
surrounding the implant. 
 Aptagel-mediated recruitment of CX3CR1+ cells requires that FKN be enriched 
locally but not sequestered permanently. Achieving this dynamic theoretically requires fast 
association (kon) and fast dissociation (koff) kinetics for aptamer-protein interactions. A fast 
kon with slow koff would likely sequester FKN, while the converse would fail to attract 
FKN. Waybrant et al., discovered FKN-aptamers against hFKN through SELEX; a process 
that selects strong-binding aptamers (fast kon, slow koff, small KD). As mFKN shares 78% 
homology with hFKN, we found FKN-aptamer kon kinetics with mFKN were akin to hFKN 
while koff kinetics were approximately four-fold faster. Thus, mFKN and hFKN associated 
equally well with FKN-aptamer, but mFKN dissociated faster; a desirable kinetic regime 
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for endogenous enrichment of mFKN. Additionally, both FKN variants had significantly 
lower affinity to FKN-aptamer (mFKN Kd = 1.2 µM, hFKN Kd = 340 nM) than FKN does 
with its cellular receptor CX3CR1 (30-740 pM)[125], allowing attracted FKN to signal to 
CX3CR1+ cells. We report a weaker hFKN interaction with FKN-aptamer than Waybrant 
et al. (Kd = 3.7 nM) likely due to methodological differences.  
Aptamers immobilized within the hydrogel matrix (i.e. aptagels) maintained catch-
and-release activity for at least one week in vitro. This activity was also demonstrated in a 
bead-based formulation (i.e. aptabeads), indicating generalizability of endogenous 
enrichment across matrix-based biomaterial platforms. DNAse dampened functionality, 
suggesting that incorporation of DNAse resistant bases may further amplify FKN 
enrichment and consequent recruitment of CX3CR1+ cells. Alternatively, maintaining 
DNAse susceptibility might be desirable to release any sequestered protein. Controlled 
inactivation of the material or bulk release of any sequestered protein could also be 
achieved via introduction of CS. 
The present study conducts the first evaluation of an aptamer-based catch-and-
release system in vivo[93, 138]. Increased numbers of non-classical monocytes and 
CD206+ macrophages near FKN-aptagels may be explained by multiple mechanisms of 
action. FKN-aptagels bind endogenous fractalkine in vivo and exhibit rapid dissociation 
rate in vitro, suggesting that FKN-aptagels may generate local FKN gradients that affect 
CX3CR1+ accumulation. Numerous studies indicate that the fractalkine-CX3CR1 axis 
promotes migration[139, 140] and survival[37, 141-143] of monocytes and macrophages. 
Non-classical monocytes, which express high levels of CX3CR1 compared to classical 
monocytes[34], may be more responsive to FKN-induced survival and migration, thereby 
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enriching this subpopulation. Given that non-classical monocytes are biased progenitors of 
M2-like macrophages[33], the observed increase in CD206+ macrophages may be caused 
by differentiation of the increased non-classical monocyte population. Additionally, FKN-
induced survival may limit monocytic cell death preventing feed forward pro-inflammatory 
responses. Recruitment of tissue-resident CD206+ macrophages to peri-implant tissue is 
also a plausible mechanism[70, 139, 140]. The FKN-CX3CR1 signaling axis is also known 
to promote adhesion[78, 144, 145] of CX3CR1+ cells. Interestingly, intra-vital microscopy 
showed decreased motility around FKN-aptagels by day 7 suggesting that recruited 
CX3CR1+ cells may increase FKN-mediated adhesion by that timepoint. Future studies 
could investigate potential progression from chemotactic to adhesive signaling. No 
significant changes in neutrophil counts were observed, corroborating an earlier 
study[131]. 
Toward the goal of clinical translation, future studies could employ computational 
modelling or experimentation with mutated or modified aptamers[86, 126] to identify if 
better enrichment kinetics exist and to enable enrichment of hFKN. The ability to alter 
formulations may enable application to diverse clinical contexts. For example, aptabeads  
or aptamer-functionalized nanoparticles[146]  may be advantageous when injury occurs 
deep within tissue and bulk hydrogel implantation is not feasible, such as after brain injury 
(e.g. trauma or stroke). Elevated FKN is associated with improved healing after brain 
injury[80-82] but while FKN levels initially rise, driving CX3CR1+ cell recruitment, they 
soon rapidly fall[127]. FKN-aptabeads could prolong CX3CR1+ cell recruitment by storing 
FKN during the early surplus and releasing it during later days as FKN levels decline. Other 
critical molecules can be targeted by identifying binding aptamers via SELEX and tuning 
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aptamer kinetics via selection pressures, mutations, truncations, and additions[86]. 
Through this, combinations of aptamers could be immobilized on biomaterials to treat 
complex pathological conditions in which regulation or enrichment of multiple proteins is 
required. 
 
3.4.2. SDF-1a-releasing aHep-N hydrogels 
Stimulating the expansion of stable vascular networks promises to improve 
therapeutic outcomes after ischemia, trauma, and tissue transplantation; however, 
engineering a therapy that potently and safely promotes vascularization remains an unmet 
clinical need. Spatial concentration of pro-angiogenic/arteriogenic therapies would 
minimize off-target risks such as stimulating rogue tumor vasculature[147, 148], while 
focusing treatment only to the injured or regenerating tissue region. Here we exploited the 
ability of PEG-DA hydrogels functionalized with N-desulfated heparin, a modified GAG, 
to localize the presentation of bioactive growth factor cargo SDF-1α[114] and spatially 
concentrate its pro-angiogenic/arteriogenic effects. Selectively desulfated heparin exhibits 
low anticoagulant activity compared to native heparin while still protecting bioactivity of 
growth factor cargo[114, 115, 117, 121].  
SDF-1α is of interest in angiogenic/arteriogenic therapies because 
pathophysiologically, SDF-1α can be secreted perivascularly by vessel-associated cells 
downstream of VEGF signaling, contributing to positioning of monocytes within a 
localized gradient of SDF-1α at the outer vessel wall[55]. While recruitment of monocytes 
has been associated with pro-angiogenic and arteriogenic metrics[6, 30, 45, 48, 51, 55, 
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149], the phenotype of SDF-1α-recruited cells has not been well characterized. Literature 
strongly associates both arteriogenesis and angiogenesis with recruitment of Ly-6Clo non-
classical monocytes and M2-like macrophages[6, 26, 52, 53]. We found that non-classical 
monocytes have higher surface expression of CXCR4, therefore yielding them more 
sensitive to SDF-1α chemotactic signals compared to classical monocytes. These data are 
in agreement with our recent finding that SDF-1α-directed chemotaxis is higher for non-
classical than classical monocytes[6]. Indeed, in the present study we showed that heparin-
functionalized hydrogels exhibiting in vitro release of SDF-1α over 3 days achieved 
increased monocyte recruitment to the peri-hydrogel space in vivo as early as 1 day 
compared to internal control. Three days after surgery, more non-classical monocytes were 
recruited to the aHep-N-SDF gel than the aHep-N gel without SDF-1. Similarly, the ratio of 
non-classical to classical monocyte was significantly higher under the aHep-N-SDF gel 
compared to the Hep-N gel less than 8mm away indicating a shift in the local tissue 
environment from inflammatory to regenerative. These data suggest that the aHep-N-SDF 
hydrogel achieves a high degree of spatial control in pro-regenerative endogenous cell 
recruitment that enables continued cellular therapeutic action outlasting SDF-1α release.  
Monocytes and monocyte-derived macrophages are key players in promoting 
angiogenesis and arteriogenesis, making them a desirable endogenous cell source to target 
for pro-regenerative immunologically smart biomaterials. During inflammatory vascular 
remodeling, select populations of perivascular monocytes and macrophages contribute 
paracrine signals to the remodeling vasculature, including secretion of growth factors such 
as platelet-derived growth factor (PDGF) and VEGF, as well as matrix-remodeling 
enzymes such as MMPs[30, 45, 48, 51, 55]. Consistent with this supportive role of 
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monocytes and macrophages in vascular remodeling, we showed in the present study that 
SDF-1α-releasing aHep-N hydrogels promoted the influx and retention of pro-regenerative 
monocytes that correlated with enhanced early and sustained arteriogenesis of small 
arterioles (< 40µm) and enhanced microvascular network density in the tissue surrounding 
SDF-1α releasing aHep-N-SDF hydrogels. Thus, localized SDF-1α delivery may increase 
blood flow critical for tissue repair processes, in part through early and selective 
recruitment of pro-regenerative monocytes. Intravital imaging allowed us to use paired data 
of change in vessel diameter and immunophenotype of monocytes around the gels. Early 
arteriolar structural changes correlated with the non-classical:classical monocyte ratio in 
tissue and the slope of the aHep-N-SDF regression line was higher than internal control. 
The difference in slope between the internal control and aHep-N-SDF gels could suggest 
that local SDF-1α further enhances the pro-arteriogenic activity of recruited non-classical 
monocytes locally through additional functional cues. Indeed, previous reports have 
suggested that VEGF induces “on-site education” of monocytes upon recruitment, 
functioning both as a recruitment signal and a knob to tune pro-regenerative function of 
the arriving cells[30]. Taken together, our data suggest that the aHep-N-SDF hydrogel 
system is a promising “immune-regenerative engineering” approach to promote 
vascularization in injured tissue through recruitment of pro-regenerative non-classical 
monocytes to the injury niche to enable or enhance their therapeutic potential. 
 
3.5. Materials and Methods 
3.5.1. Fractalkine aptagel experiments 
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Aptagel materials 
Sequences of the FKN-binding oligonucleotide (FKN-aptamer, 5’-
GGGGTGGGTGGGGGGCACGTGTGGGGGCGGCCAGGGTGCT-3’) and scrambled 
oligonucleotide (SCR-aptamer, 5’-
CTATCGGCGACATGAACTTTGGCAAGGGCATCTGGTCCAT-3’) were obtained 
from Waybrant et al[125]. The oligonucleotides (5’-Acrydite-, amino-modified, or 
unmodified) and their complementary sequences (CS) were synthesized and purchased 
from Integrated DNA Technologies.  Recombinant human (h), mouse (m) or rat (r) 
fractalkine protein (with or without BSA carrier), and DuoSet ELISA preparation kits were 
purchased from R&D Systems. Ammonium persulfate (APS) and N,N,N’,N’-trimethylene 
diamine (TEMED) were purchased from BioRad. Poly(ethylene glycol) diacrylate 
(PEGDA, Mn = 700) for aptagel synthesis was purchased from Sigma-Aldrich. NHS-
activated agarose resin for aptabead synthesis was purchased from ThermoFisher.  
 
Surface Plasmon Resonance 
The binding kinetics of the protein-aptamer interactions were assessed by surface 
plasmon resonance (SPR) on a Biacore T200 instrument at 25 °C in PBS running buffer 
(Gibco; 2.966 mM Na2HPO4×7H2O, 1.059 mM KH2PO4, 155.172 mM NaCl, pH 7.4). 
Immobilization of FKN protein to a CM5 sensor surface was performed via amine coupling 
chemistry at a flow-rate of 5 µL/min, following standard procedures recommended by the 
manufacturer. Briefly, CM5 sensor surfaces were activated with a 7-min injection of N-
Hydroxysuccinimide/1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride 
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(NHS/EDC), followed by injection of FKN, and deactivation of the surfaces with a 12-min 
injection of ethanolamine-HCl. For initial screening studies, fractalkine variants (50 
µg/mL, 10 mM NaCH3COO pH 5.0) were injected on separate flow cells for 3-4 minutes 
to give final immobilization levels of ~2000 RU. For kinetic experiments, FKN variants 
(10 µg/mL in 10 mM NaCH3COO, pH 5.0) were injected on separate flow cells for 60-90 
seconds to give final immobilization levels of ~400 RU for hFKN and ~800 RU for mFKN. 
Mouse serum albumin (MSA) was employed as a negative surface control. Kinetic 
evaluation was performed by sequential 3-min injections of varying concentrations (10-
1000 nM) of FKN- and SCR-aptamers, followed by a 10-min dissociation phase at a flow 
rate of 30 µL/min. Surfaces were regenerated between analyte injections with a 30-second 
injection of 20 mM NaOH, 1 M NaCl. Data analysis and curve fitting of MSA subtracted 
curves was performed with the Biacore T200 Evaluation Software (v2.0) using the 
heterogeneous ligand model. Due to the ligand surface density required to achieve 
sufficient signal detection, rebinding of analytes manifested as a biphasic dissociation 
curve. However, the fast-kinetic components of each fit accounted for greater than 80% of 
the observed binding and were reported for each interaction. 
 
Chemistry and Synthesis of Aptagels and Aptabeads 
Synthesis of aptamer-functionalized hydrogels was modified from Battig et al[150] 
and Krieger et al[27]. Aptagel molds were created by separating two glass slides with 0.5 
mm of scotch-tape layered and sealed on the periphery. Acrydite-modified or unmodified 
aptamers (1 mM stock, 318.5 µM final) were mixed with PEGDA-700 (5% w/v final) and 
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APS (0.3 M stock, 18 µM final) and the solution was vortexed. TEMED (0.3 M stock, 18 
µM final) was added and the solution was quickly injected into the mold. After five 
minutes, the mold was taken apart, extra liquid was blotted dry, and 2-mm disks were 
punched out and transferred to PBS in a low-binding 96-well plate for washing. The disks 
were washed with fresh PBS at least 4 times over 4 hours. Each disk contained ~500 pmol 
of aptamer. Thus, for 12 to 15 disks (100 µL), the recipe consisted of: 51.70 µL PBS, 4.45 
µL PEGDA, 31.85 µL aptamers (1 mM), 6 µL APS (0.3 M) and 6 µL TEMED (0.3 M). 
For in vivo experiments, the glass aptagel molds and PEGDA solution were first sterilized 
in a UV oven for 30 minutes; APS and TEMED solutions were passed through a 0.22 µm 
cellulose filter; aptamers were reconstituted in sterile, nuclease-free H2O. Aptagel 
synthesis took place under a laminar-flow cell culture hood. 
Aptabeads were prepared based on instructions provided by the NHS-activated 
agarose bead manufacturer. Briefly, 5’-amino-modified aptamers were mixed at 
concentrations of either 0.25 nmol/mg or 1 nmol/mg to batches of 50 mg of dry agarose 
beads and allowed to conjugate on a rotisserie shaker. Unreacted NHS groups were 
neutralized with Tris buffer.  
 
Fluorescence Staining and Imaging of Aptagels 
Hydrogels either functionalized with acrydite-modified FKN-aptamers, mixed with 
unmodified aptamers or without aptamers, were stained with fluorescein-tagged (6-FAM) 
complementary sequence (fCS) to the aptamer. fCS was diluted in 1% BSA 500-fold and 
the aptagels were incubated on a shaker overnight at room temperature. The aptagels 
 50 
required washing at length to remove background fluorescence; studies to replicate our 
findings should begin with a more diluted fCS stain. The aptagels were imaged on a Leica 
SP5 Confocal Microscope with a 10X objective lens and a 488-nm argon laser. Slices were 
taken at 6 µm for a total depth of 100 µm. The imaging dimensions were 1920X1920 µm. 
 
In vitro experiments 
Experiment paradigm: mFKN was diluted in 1% or 5% BSA to the desired 
concentration and reverse pipetted into a low-binding 96-well-plate either with or without 
FKN- or SCR-aptagels. The plate was sealed and placed on a shaker at 300 rpm for 24 hrs. 
at room temperature. The total solution was then pipetted out and stored as Day 0 (unbound 
mFKN) samples. The gels were washed in their wells thrice (Fig. S2C) with wash media 
(1% BSA in phosphate buffered solution) to remove non-specifically bound mFKN. To 
initiate passive release experiments, fresh solutions of 1% BSA were added and left for 24 
hrs. The total solution was removed, stored and replaced with fresh solution each day. 
Samples were either kept at 4°C if being assayed with ELISA the following day or at -20°C 
until the assay. One group of aptagels was pre-treated with 25 units of DNAse 
(ThermoFisher) at 37°C for 1 hour, before beginning the paradigm. All aptagels were 
studied in at least triplicate or quadruplicate per experiment and the experiments were 
repeated multiple times. 
 Protein quantification: Samples were analyzed with ELISA, following the 
manufacturer’s instructions, after diluting them to the detectable range. We reliably 
observed high sensitivity towards recombinant mFKN and thus primarily report relative 
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differences between aptagels and controls instead of raw amounts. ELISA plates were read 
on a SpectraMax i3X Multi-mode plate reader at 450 nm with background subtraction at 
570 nm. Duplicate technical replicates were averaged and the blank optical density was 
subtracted.  
 
Dorsal Skin Window Chamber Surgery and Aptagel Implantation 
All animal procedures were conducted per protocols approved by the Georgia Tech 
Institutional Animal Care and Use Committee. Male C57Bl/6 mice aged 11-15 weeks were 
anesthetized with vaporized isoflurane at 5% concentration and maintained under 
anesthesia at 1-3%. Sustained release buprenorphine (1.2 mg/kg, i.p.) was delivered pre-
operatively as an analgesic. Dorsal skin was shaved, depilated, and sterilized using ethanol 
and chlorhexidine. A double-layered skinfold was elevated off the back of the mouse, and 
the back side of the titanium window chamber frame was surgically fixed to the underside 
of the skinfold. A circular area (diameter 12 mm) of epidermis and dermis on the top-side 
of the skinfold was removed using surgical micro-scissors to reveal the vasculature 
underlying the reticular dermis. Exposed tissue was kept hydrated with sterile saline. The 
front side of the titanium frame was then mounted on the top of the dissected tissue and 
attached to its underlying counterpart, and then the dorsal skin was sutured to the two 
titanium frames. An aptagel was placed near the edge of the window closest to the body, 
and the chamber was sealed with a sterile glass coverslip. Mice recovered in clean heated 





Mice were euthanized by CO2 asphyxiation and the hydrogel was explanted to 
measure sequestered mFKN via ELISA as described above. 4-mm diameter biopsy 
punches were used to harvest the dorsal tissue under the gel (“near” region) and tissue on 
the opposite side of the window (“far” region). Single cell suspensions were generated by 
mincing the tissue, digesting in collagenase IA (Sigma; C9891) for 45 min at 37˚C, and 
straining through 40 µm pore filters. Cell suspensions were immunostained using standard 
flow cytometry techniques. The following antibody panel was used: PerCP/Cy5.5-CD45 
(BioLegend; clone 30-F11), APC/Cy7-Ly6G (BioLegend; clone 1A8), PE-MerTK (R&D 
Systems; clone 108928), BV711-CD64 (BioLegend; clone X54-517.1), BV510-CD11b 
(BioLegend; clone M1/70), APC-Ly6C (BioLegend; clone HK1.4), BV421-CD11c 
(BioLegend; clone N418), and BV605-CD206 (BioLegend; clone C068C2). Samples were 
analyzed using a BD FACS Aria IIIu Cell Sorter. Positive versus negative expression of 
each marker was determined using fluorescence-minus-one controls derived from excess 
dorsal tissue. Immunophenotypes were identified as follows: macrophage, CD45+ CD11b+ 
CD64+ MerTK+; M2-like macrophage, CD45+ CD11b+ CD64+ MerTK+ CD206+; 
monocyte, CD45+ CD11b+ NOT(CD64+ MerTK+) CD11c- SSClo; non-classical monocyte, 
CD45+ CD11b+ NOT(CD64+ MerTK+) CD11c- SSClo Ly6Clo; neutrophil, CD45+ CD11b+ 
NOT(CD64+ MerTK+) CD11c- Ly6G+ (Fig. S4). 
 
High-dimensional analysis of flow cytometry data 
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t-Distributed Stochastic Neighbor Embedding (t-SNE) high-dimensional analysis 
on 9-parameter flow cytometry data was performed. Prior to tSNE dimensional reduction, 
each sample was pre-gated on CD45+CD11b+ single cells, and then downsampled to 1000 
events in FlowJo Version 10.2. For samples with fewer than 1000 events, no downsampling 
was performed (the smallest number of CD45+CD11b+ single cells in a sample was 978). 
After downsampling, each sample was assigned an electronic barcode and all samples were 
concatenated to enable generation of a single composite tSNE map that utilized data points 
from all samples (16 total samples: 4 SCR near, 4 SCR far, 4 FKN near, 4 FKN far). tSNE 
analysis was performed in FlowJo software using all surface markers and the following 
parameters: 1000 iterations, 30 perplexity, 200 eta (learning rate), and 0.5 theta.  
 
4D analysis of cell migration dynamics 
Male heterozygous B6.129P-Cx3cr1tm1Litt/J (CX3CR1-EGFP) mice were utilized 
to visualize monocytes and macrophages in vivo based on their selective surface expression 
of CX3CR1. Aptagels were labelled fluorescently via incorporation of Alexa Fluor 647 
conjugated, acrydite-modified SCR-aptamer (1% of total aptamer). Time lapse videos of 
CX3CR1+ cell migration were generated by confocal intra-vital microscopy 7 days after 
dorsal skin window surgery and aptagel implantation. Briefly, mice were anesthetized 
using vaporized isoflurane and secured in a heated custom stage, the glass window was 
removed, and dorsal tissue was irrigated with sterile saline. Aptagels and CX3CR1+ cells 
were visualized via 633nm and 488nm excitation, respectively, using a 20X water-
immersion lens (NA = 1.0) and a Zeiss LSM 710 NLO confocal microscope. Time lapse 
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z-stacked videos (period = 30s) were acquired near the edges of FKN and SCR aptagels. 
For 4D analysis in Imaris (Bitplane), cells expressing CX3CR1-EGFP were identified 
using the surface tool. CX3CR1+ surfaces were identified by smoothing with a 2 µm 
grain size and an automatic threshold on absolute intensity. Touching objects were split 
using a seed points diameter of 10 µm. CX3CR1hi cells were discriminated from all other 
CX3CR1+ cells by applying a filter to select surfaces with a high fluorescence intensity 
in the CX3CR1-EGFP channel. To quantify migration dynamics, the automatic cell 
tracking feature was selected, and track displacement, track length, track straightness, and 
speed were analyzed. 
 
Statistical Analysis 
Statistical analysis was performed in GraphPad Prism. Outliers were identified and 
removed using Grubbs’ test (alpha = 0.05). Sample sizes and statistical tests are stated in 
each figure legend. 
 
3.5.2. SDF-1a-releasing aHep-N hydrogel experiments 
Heparin chemical modification  
Heparin sodium salt (Sigma) was reconstituted with distilled, deionized water 
(ddH2O) at 10mg/mL and desalted using Dowex 50WX4 resin (mesh size 100-200, Sigma), 
adding pyridine until the pH reached a value of ~6, as previously described[114]. The 
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solution was reduced and excess pyridine was eliminated using a rotary evaporator (Buchi) 
before being flash frozen and lyophilized to yield heparin pyridinium salts. The heparin 
pyridinium salts were then dissolved in solution of 90% DMSO/10% ddH2O (v/v) at a 
concentration of 1mg/mL. The solution was mixed for 2h at 50°C in a rotary evaporator 
and then cooled on ice and precipitated by an equal volume of 95% ethanol (VWR) 
saturated with sodium acetate (VWR). The precipitate was centrifuged and washed with 
ethanol prior to dissolving in distilled water (dH2O). The solution was dialyzed for 3 days 
with daily exchanges of dH2O and then lyophilized (Labconco). Finally, the product was 
functionalized using a 8.0 molar excess of of N-(3-aminopropyl) methacrylamide 
hydrochloride (APMAm, Polysciences), N-hydroxysuccinimide (NHS, Acros Organics) 
and N-3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDC, Sigma) at an 
acidic pH.  After functionalization, the solution was dialyzed and lyophilized again as 
described previously.  The finished product was stored at -20°C until use.  
PEG-DA synthesis 
Distilled methylene chloride (DCM) was used to dissolve 3.4 kDa PEG in a three 
neck round-bottom flask and stirred under nitrogen flow. First, triethylamine in DCM at a 
1:1 molar ratio with the PEG was added. Subsequently, a 100% molar excess of acryloyl 
chloride (AcCl) in 15-20mL of DCM was added dropwise. Following the AcCl addition, 
the system was closed and kept under nitrogen overnight. Potassium carbonate (K2CO3) 
was then added to the solution to remove trimethylamine hydrochloride by-product created 
in the previous step. After separation of the organic phase, the PEG-DA was precipitated 
using cold diethyl ether and dried overnight at RT. The finished product was stored at -
20°C until use. 
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Hydrogel fabrication  
PEG-DA and N-desulfated heparin (Hep-N) were used as a mixture of 90:10 by 
weight in all hydrogels. These polymers were UV sterilized and combined at a 10 wt% 
total solution ratio with sterile phosphate buffered saline (PBS), thermal initiators 
ammonium persulfate (APS, 0.018M, Sigma) and N,N,N’,N’-tetramethylethane-1,2-
diamine (TEMED, 0.018M, Sigma), and an amount of GMP-quality bovine serum albumin 
(BSA, Sigma #A8412) equivalent to 50 wt% of the solution. The solution was then pipetted 
between two sterile glass slides with an inner clearance of 500µm. The solution was 
allowed to gel at 37°C for 10 min before the gels were punched out using a 2mm (diameter) 
biopsy punch (Miltex).  The resulting hydrogels were discs of 0.5mm thickness and 2mm 
diameter.  
NMR Analysis of heparin and PEG-DA polymers 
Proton nuclear magnetic resonance (1H NMR) was used to characterize the 
polymers used for hydrogel fabrication (Figure 16). Samples of N-desulfated heparin 
methacrylamide (Hep-N Mam) and poly(ethylene glycol) diacrylate (PEG-DA) were 
diluted to a concentration of 10 mg/mL with deuterated water (D2O) and 1H NMR was 
measured on a Bruker Avance III 400 spectrometer at 400 MHz. To determine the degree 
of functionalization of the Hep-N MAm derivative, first the contributions of N-acetyl 
protons in un-functionalized specimens were determined (Figure 16a). Subsequently, the 
ratio of protons donated by methacrylate groups was multiplied by the native N-acetyl 
groups from unfunctionalized samples (Figure 16b). The contribution of native methyl 
groups in non-methacrylated material was approximately 8-9%. The degree of 
 57 
functionalization in Hep-N MAm was ~20% for the in vitro assays in Figure 10. For the 
characterization of PEG-DA, the presence of acrylate peaks around 5.8-6.4 ppm were 
observed (Figure 16c).  
 
Figure 16. NMR analysis of polymers. (A) NMR spectrum of Hep-N is used to find native 
N-acetyl contributions from un-functionalized samples. The contribution of native methyl 
groups in non-methacrylated material is 8-9%. (B) NMR spectrum of Hep-N Mam shows 
~20% functionalization of Hep-N polymer with MAm. (C) NMR spectrum of PEG-DA. 
Acrylate peaks (5.8-6.4ppm) are labeled. 
SDF-1α loading and in vitro release  
Gels were placed in ultra-low binding 24-well plates and rinsed with PBS for 3h 
rinse prior to loading with recombinant murine SDF-1α (Peprotech) overnight at 4°C. 
During this time, each gel was incubated with a 10µL droplet of PBS containing 0.1µg 





of PBS and incubated at 37°C for the release study. PBS was exchanged at appropriate 
timepoints and stored at -20ºC for subsequent analysis. 
In vitro migration  
SDF-1α loaded gels (aHep-N-SDF) or albumin loaded control gels (aHep-N) were 
incubated with 650µL of Iscove’s Modified Dulbecco’s Medium (Fisher) containing 0.5% 
fatty acid-free bovine serum albumin (Fisher) for 24h at 37°C. A transwell assay was 
assembled by transferring hydrogel-conditioned media to the chamber below a 5µm pore 
size membrane, and seeding 4x105 cells from C57BL/6 mouse bone marrow aspirate on 
top. After 4h of migration at 37°C and 5% CO2, migrated cells were stained with DRAQ5 
dye according to manufacturer’s protocol (Cell Signaling Technologies). Relative 
migration was quantified by fluorescence intensity using an Odyssey CLx Infrared Imaging 
System (LI-COR Biosciences).  
Chimeric mice  
All animal procedures were conducted according to protocols approved by the 
Georgia Tech Institutional Animal Care and Use Committee. For generation of mice with 
chimeric EGFP-labeled bone marrow, male C57BL/6 recipient mice, 8-10 weeks of age, 
were lethally irradiated with a total dosage of 10.5 Gy (5.5-Gy and 5-Gy doses, 3h apart) 
using an x-ray source (Radsource 2000). Animals were given water supplemented with 
Baytril for 1 week before and 2 weeks after irradiation and bone marrow cell 
transplantation. Transplants were performed by injecting 1x107 bone marrow cells 
harvested from transgenic EGFP (donor) mice into the jugular vein of recipient mice under 
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inhaled isoflurane anesthesia. Mice were allowed to recover for at least 4 weeks prior to 
surgery.  
Dorsal skinfold window chamber  
Male C57BL/6 mice aged 8-12 weeks of age were anesthetized by i.p. injection of 
a mixture of ketamine (100mg/kg) and xylazine (10mg/kg) in sterile 0.9% saline and 
surgically fitted with sterile dorsal skinfold window chambers (APJ Trading Co.) as 
previously described[6, 53, 151, 152]. Briefly, dorsal skin was shaved, depilated, and 
sterilized via triplet washes of 70% ethanol and chlorhexidine. A double-layered skin fold 
was elevated off the back of the mouse and the back side of the titanium window chamber 
frame was surgically fixed to the underside of the skinfold. Surgical microscissors were 
used to remove the epidermis and dermis from the top-side of the skinfold in a circular area 
(diameter = 12mm) to reveal the vasculature underlying the reticular dermis. Exposed 
tissue was kept hydrated with sterile saline. The front side of the titanium frame was then 
mounted on the top of the dissected tissue and attached to its underlying counterpart. The 
dorsal skin was sutured to the two titanium frames, and the exposed tissue was sealed with 
a protective sterile glass coverslip. Mice were allowed to recover in heated cages and 
administered sustained release buprenorphine via i.p. injection as a postoperative 
analgesic. All mice received a laboratory diet and water ad libitum throughout the course 
of the experiment. 
Hydrogel placement and intra-vital brightfield microscopy  
Hydrogels were implanted into the window chamber on the day of surgery (day 0). 
Mice were anesthetized via inhaled isoflurane, the glass window was removed and dorsal 
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tissue was flooded with 1mM adenosine in Ringer’s solution to maximally dilate all vessels 
and maintain tissue hydration. The mouse was then mounted to a custom microscope stage 
mount and imaged noninvasively at 5X magnification on a Zeiss Imager.D2 microscope 
with AxioCam MRc 5 color digital camera (Carl Zeiss). Images were acquired on day 0 
immediately preceding hydrogel implantation and again on day 3 or 7 according to 
experimental design. Mice were implanted with one Hep-N internal control hydrogel and 
one aHep-N experimental hydrogel (unloaded or loaded with SDF-1α) placed on opposite 
sides of the window. 
Changes in microvascular length density 
Microvascular length density measurements were made by intravital brightfield 
microscopy and whole mount immunofluorescence. A 4mm (diameter) region of interest 
circumscribing the hydrogel and tangential to the gel edge was selected as indicated in 
Figure 17. Vessels visible within these cropped images were traced and total vessel length 
per unit area was quantified using ImageJ.  
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Figure 17. Analysis of CD31+ microvessels. (A-B) CD31+ vessels were visualized by 
whole mount immunofluorescence microscopy at day 7 and traced to quantify length of the 
microvascular network. (C) aHep-N-SDF hydrogels significantly increase microvascular 
network length compared to internal control while aHep-N controls show no change. (Scale 
bar = 1 mm). (D) Region of interest is 4mm diameter circle circumscribing the gel. 
 
Measurement of change in arteriolar diameter  
To measure changes in arteriolar diameter, arteriole–venule pairs were identified 
within a 3mm radius of the center of each gel. Arterioles and venules were identified on 
the basis of size and morphology at day 0; venular diameters were larger than arteriolar 









































Figure S4: Analysis of CD31+ microvessel density. (A-B) CD31+ vessels were visualized by whole
mount immunofluorescence microscopy at day 7 and traced to quantify length of the microvascular
network. (C) aHep-N-SDF hydrogels significantly increase microvascular network length compared to
internal control (same as Figure 7G) while aHep-N controls show no change. (Scale bar = 1 mm). (D)





were measured using Zen Blue (Zeiss) and recorded longitudinally for each vessel 
segments on day 0 and 3 or day 0 and 7 (Figure 18). Day 0 diameter measurements were 
used to bin vessels less than 40µm in diameter[129]. This metric is limited to vessels visible 
at both time points (1-4 vessels/gel). 
 
Figure 18. Representative intravital microscopy of arteriolar remodeling. Change in 
lumenal diameter of arterioles (arrowheads) is negative for internal controls and aHep
-N
 
control and positive for aHep
-N
-SDF hydrogels at (A, B) day 3 and (C, D) day 7. (Scale bar 
= 1 mm). 
 
Hydrogel removal, tissue harvest, and preparation for single-cell suspensions  
To visualize the recruitment of cells to the hydrogel interface, hydrogels were 
explanted onto glass slides and imaged at 5X magnification. For subsequent flow 
cytometry analysis, cells were then removed from the hydrogel surface by incubation with 
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trypsin for 10min at 37°C and combined with a fixed volume of flow cytometry counting 
beads for quantification of relative cell number, CountBrightTM Absolute Counting Beads 
(Life Technologies). To measure the recruitment of cells to tissue by day 3, the dorsal tissue 
was bisected along the midline separating the hydrogels, digested with 1mg/mL 
collagenase at 37°C, and further disaggregated with a cell strainer to create a single cell 
suspension.  
Flow cytometry  
Immuno-staining and flow cytometry analyses were performed according to 
standard procedures and analyzed on a FACS-AriaIIIu flow cytometer (BD Biosciences). 
The following antibodies were used for cell phenotyping: APC/Cy7-conjugated anti-
CD11b (BioLegend, M1/70), APC-conjugated anti-Ly-6C (BioLegend, HK1.4), and PE- 
or PerCP/Cy5.5-conjugated anti-CXCR4 (eBiosciences, 2B11). CD11b+SSClowLy-
6Chigh/low monocyte populations were confirmed to be Ly-6Gneg. 
Whole mount immunohistochemistry and intravital confocal microscopy  
Mouse vasculature was perfused with warm 0.9% saline and then 4% PFA until 
tissues were fixed. Dorsal tissue was explanted and drop-fixed in 4% PFA for 10min, 
permeabilized with 0.2% saponin in PBS for 16-24h at 4°C, blocked with 10% mouse 
serum in PBS for 16-24h, and stained with combinations of the following monoclonal 
antibodies diluted into a solution of 0.5% BSA, 5% mouse serum, and 0.1% saponin in 
PBS: Cy3-conjugated anti-⍺-smooth muscle actin (αSMA, 1:300, Sigma), AF594-
conjugated anti-CD31 (1:100, BioLegend), AF647-conjugated anti-CD68 (1:200, AbD 
Serotec), and AF488-conjugated anti-CD206 (1:200, AbD Serotec). Images of dorsal tissue 
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vessel networks were acquired as 3-dimensional z-stacked tile scans in confocal and 
multiphoton modes using a Zeiss LSM710 NLO microscope, Ti:Sapphire pulsed IR laser, 
and 5X, 10X, or 20X magnification. Male heterozygous B6.129P-Cx3cr1tm1Litt/J 
(CX3CR1-EGFP) mice were utilized to visualize monocytes in live mice based on their 
selective surface expression of CX3CR1[6, 34]. Intravital confocal visualization of 
CX3CR1high and CX3CR1+ cells in/near peri-implant venules was performed in (CX3CR1-
GFP) knock-in transgenic mice after jugular vein injection of rhodamine-conjugated 
isolectin B4 (0.1mg/50µL; Vector Laboratories) to visualize perfused vasculature on day 1 
after surgery. One 20X region of interest adjacent to each gel implant was imaged on day 
1 after surgery and immediately after infusion of fluorescently tagged lectin to visualize 
vessels. Intravital confocal imaging was conducted with a 20X water immersion objective 
(NA=1.0). CX3CR1+ cell numbers were quantified using Fiji and 3D surface rendering was 
performed in Imaris (Bitplane). 
Statistical analysis  
Data are presented as mean ± standard error of the mean (SEM) unless otherwise 
indicated. Paired data for internally controlled studies were analyzed in paired t-tests or by 
ANOVA with repeated measures. Multiple comparisons were made by one- or two-way 
ANOVA followed by Bonferroni or Sidak post-tests to compare means. Linear regression 
analysis was performed separately on the internal control group and experimental group 
and r2 values are reported. All statistical analysis was done in GraphPad Prism software. 
Unless otherwise noted, p<0.05 was considered statistically significant. 
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4. SYNERGY BETWEEN CHEMOKINE AND SPHINGOLIPID 
SIGNALS IN MONOCYTE RECRUITMENT AND 
VASCULARIZATION OF INJURED SKIN2 
4.1. Abstract 
The immune response to biomaterial implants critically regulates functional 
outcomes such as vascularization, transplant integration/survival, and fibrosis. To create 
“immunologically smart” materials, the host-material response may be engineered to 
optimize the recruitment of pro-regenerative leukocyte subsets which mature into 
corresponding wound healing macrophages. We have recently identified that a unique 
feature of pro-regenerative Ly6Clow monocytes is a higher expression of both the bioactive 
lipid receptor sphingosine-1-phosphate receptor 3 (S1PR3), and the stromal derived factor-
1α (SDF-1α) receptor, CXCR4. Therefore, we designed a bi-functional hydrogel to 
harnesses a mechanistic synergy between these signaling axes to enhance the recruitment 
of endogenous pro-regenerative monocytes. To overcome the challenge of co-delivering 
two physiochemically distinct molecules—a large hydrophilic protein and hydrophobic 
small molecule—we engineered a dual affinity hydrogel that exploits the growth factor 
affinity of a modified heparin (Hep-N) and lipid chaperone activity of albumin. The 
sphingosine analog FTY720 and SDF-1α are successfully loaded and co-released from the 
                                                
2 Adapted from: M.E. Ogle, J.R. Krieger, L.E. Tellier, J. McFaline-Figueroa, J.S. 
Temenoff, E.A. Botchwey, Dual Affinity Heparin-Based Hydrogels Achieve Pro-
Regenerative Immunomodulation and Microvascular Remodeling, ACS Biomaterials 
Science & Engineering  (2017). Reprinted by permission of ACS Publications. 
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Hep-N-functionalized PEG-DA hydrogels while maintaining bioactivity. Placement of 
these hydrogels into a murine partial thickness skin wound demonstrates that co-release of 
FTY720 and SDF-1a yields superior recruitment of myeloid cells to the implant interface 
compared to either factor alone. While in vivo delivery of FTY720 or SDF-1α individually 
promotes the enhanced recruitment of Ly-6Clow non-classical monocytes, co-delivery 
enhances the early accumulation and persistence of the differentiated wound healing 
CD206+ macrophages in the tissue surrounding the gel. Co-delivery similarly promoted the 
synergistic expansion of vasculature adjacent to the implant, a key step in tissue healing. 
Taken together these findings suggest that the combination of chemotactic molecules may 
provide additional maturation signals to the infiltrating leukocytes to facilitate macrophage 
transition and vascular network expansion, thus, ultimately, potentiating tissue repair. The 
coupling of multiple pro-regenerative biological cues provides a foundation for more fine-
tuned immunoregenerative modulation to facilitate tissue repair. 
	
4.2. Introduction 
Endogenous inflammatory response in sterile injury and tissue trauma is 
characterized by the infiltration of circulating mononuclear phagocytes to clear debris, 
remodel extracellular matrix and vasculature, and signal to circulating and parenchymal 
cells that help restore the native cellular and matrix composition[10]. Loss of function 
studies show that early myeloid cell input is critical for effective repair of tissue injury in 
the complex tissue regeneration models of the salamander limb and zebrafish tail fin[12, 
153]. Monocytes and their macrophage progeny participate in processes of 
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angiogenesis[48] and arteriogenesis[52] while orchestrating healing across myriad injury 
contexts including liver[31], kidney[154], cardiac and skeletal muscle[1, 61, 134, 155], and 
peripheral nervous tissue[2, 5, 70]. Circulating blood monocytes are comprised of at least 
two functionally distinct subsets[34] and the inflammatory index, or balance of 
regenerative to inflammatory myeloid cells, in the tissue is correlated with the healing 
outcome[2, 6, 27, 156]. Classical monocytes are characterized by high Ly6C and low 
CX3CR1 surface expression in mice and CD14+CD16- in humans. Non-classical 
monocytes express low levels of Ly6C and high CX3CR1 in mice and CD14lowCD16+ in 
humans[34]. Monocyte-derived macrophages similarly exhibit functional and phenotypic 
heterogeneity with a spectrum of M1 “inflammatory” to M2 “regenerative” macrophages 
and the dominant presence of M2 versus M1 macrophages is related to positive healing 
outcomes[10]. Biomaterial-mediated strategies to change the inflammatory index of the 
tissue improves metrics of regeneration[2, 6, 27, 28]; therefore, development of materials 
that can effectively control the recruitment, polarization, and activity of myeloid cells 
presents an opportunity for supporting a powerful endogenous repair system[6, 27]. 
 Controlled drug delivery can facilitate spatial and temporal control over 
presentation of biological or pharmacological factors within a wounded tissue. Using 
biomaterials to produce in vivo gradients of immunomodularory cues can facilitate 
recruitment of endogenous pro-regenerative cells to the injury microenvironment[10, 27, 
53].  To control the frequency and selectivity of endogenous inflammatory cell recruitment, 
we have investigated receptor signaling axes that govern selective recruitment of monocyte 
subsets. Two such control points for manipulating the balance of functional phenotypes of 
monocytes/macrophages within inflamed tissues are the bioactive lipid receptor 
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sphingosine 1-phosphate receptor 3 (S1PR3) and CXC-type chemokine receptor 4 
(CXCR4)[6, 27, 53]. Non-classical monocytes display a higher expression of S1PR3[6] 
and CXCR4[27] at the cell surface compared to classical monocytes. Following 
inflammatory injury, upregulation of stromal derived factor-1α (SDF-1α), the natural 
ligand of CXCR4, promotes tissue repair in part by attracting and retaining myeloid cells 
near vessels to coordinate leukocyte-assisted angiogenesis and arteriogenesis[55, 157]. 
Antagonism of CXCR4 during the injury response leads to a significant reduction in 
recruited myeloid cells and a failure of neovascularization[55]. Localized biomaterial-
mediated delivery of exogenous SDF-1α enhances the recruitment of non-classical 
monocytes to inflamed tissue vasculature and concomitant expansion of microvascular 
networks within the injury niche[27]. Similarly, delivery of FTY720, a small molecule 
agonist of S1PR3, from degradable polymers stimulates selective recruitment of non-
classical monocytes from blood and their pro-regenerative on-site education, as indicated 
by their strategic perivascular positioning, attenuated secretion of inflammatory cytokines, 
and differentiation to CD206+ M2 macrophages[6]. Molecular cross-talk between S1PR3 
and CXCR4 evidenced by transactivation of CXCR4 upon S1PR3 stimulation in 
endothelial progenitor cells suggests potential synergy between these axes for 
chemotaxis[158]. Stimulation of S1PR3 also enhances CXCR4-mediated chemotaxis of 
non-classical monocytes toward SDF-1a, whereas classical monocytes fail to migrate 
robustly toward SDF-1a[6]. S1PR3 agonism enhances CXCR4 activation in endothelial 
progenitor cells, thereby enhancing their homing efficacy in the treatment of hind limb 
ischemia[158]. These results suggest that dual stimulation of S1PR3 and CXCR4 signaling 
axes in vivo through localized gradient release within an inflammatory injury niche would 
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promote synergistic recruitment of pro-regenerative monocytes/macrophages and enhance 
microvascular growth and remodeling[10, 27, 157].   
To investigate the functional synergy of the CXCR4 and S1PR3 signaling axes, we 
engineered a dual-affinity heparin-based biomaterial carrier to co-release SDF-1a and S1P 
receptor targeted small molecule FTY720. Heparin is a glycosaminoglycan that binds 
cationic proteins such as SDF-1α and protects them from denaturing conditions[114, 115, 
117]. We have previously demonstrated that matrices functionalized with a heparin 
derivative protect proteins against denaturation to maximize bioactivity and lower the 
payload requirement for in vivo efficacy[113, 114]. To reduce the anti-coagulant activity 
of heparin for safe use in vivo, we incorporated a cross-linkable heparin derivative that was 
selectively desulfated at the -N position (Hep-N)[114] within a poly(ethylene glycol) 
diacrylate (PEG-DA) network. To overcome the physiochemical disparities between SDF-
1a, a 10 kDa hydrophilic protein, and FTY720, a 307 Da hydrophobic small molecule 
lipid, the scaffolds were further engineered for dual affinity by encapsulation of albumin 
within the matrix during crosslinking (aHep-N) as an affinity-based carrier for the small 
molecule FTY720 due to its endogenous chaperone binding capacity for bioactive 
lipids[159].  
In this study, we investigated inflammatory and arteriogenic responses to aHep-N-
PEG-DA hydrogel implants releasing either SDF-1α or FTY720 or both factors combined. 
We show that SDF-1a and FTY720 are co-released from aHep-N-PEG-DA gels over 
several days in vitro. The dorsal skinfold window chamber model, a mouse model of 
excisional skin injury, was used to longitudinally assess the recruitment of innate immune 
cells and associated microvascular network expansion. Synergy between SDF-1a and 
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FTY720 was observed with regard to leukocyte attachment to the implant surface and 
structural enlargement of arterioles in the peri-implant tissue. Accumulation of 
macrophages in the early phase of repair and wound-resolving macrophages in the later 
phase was enhanced by co-delivery of SDF-1a and FTY720 compared to either factor 
alone. These results suggest an exciting potential of the aHep-N-PEG-DA hydrogel 
technology to release multiple distinct biomolecular cues and locally tune the innate 
immune response in favor of regeneration. 
 
4.3. Results 
4.3.1. aHep-N-PEGDA hydrogels co-release bioactive SDF-1a and FTY720 in 
vitro 
The sphingosine analog FTY720 enhances the migration of non-classical 
monocytes toward an SDF-1a gradient in vitro[6]. To harness this biological synergy, we 
sought to develop a biomaterial that could release both the small molecule FTY720 and the 
protein SDF-1a to locally deliver these agents in vivo. Hydrogels containing a heparin 
derivative and embedded with albumin were engineered to sequester and release these 
physiochemically distinct biomolecules. The albumin provides an affinity carrier for small 
bioactive lipids or small molecule analogs such as FTY720[159], while the heparin 
derivative provides a platform for loading and stabilizing heparin-binding growth 
factors[27, 114, 115]. The fabrication and composition of aHep-N hydrogels encapsulating 
the chemokine protein SDF-1α and hydrophobic small molecule FTY720 are shown in 
Figure 19a. The dual loaded gels release 24.9 +/- 7.2 % of total SDF-1α payload by day 1 
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and 26.0 +/- 0.2 % by day 7 in vitro (Figure 19b); while 43.0 +/- 4.0 % of FTY720 is 
released by day 1 and 87.2 +/- 2.1% by day 7 (Figure 19b). Both FTY720 and SDF-1α 
released from the gels maintain bioactivity as illustrated by their ability to induce 
chemotaxis of primary murine bone marrow cells toward 24h hydrogel-conditioned media 
in an in vitro transwell migration assay. Media conditioned by gels releasing SDF-1α 
induced a 1.5-fold increase in chemotaxis compared to control gels containing only 
embedded albumin, while gels releasing both FTY720 and SDF-1α induced a 2.0-fold 
increase compared to control (Figure 19c). 
 
Figure 19. Hep-N-PEG-DA hydrogels co-release bioactive SDF-1a and FTY720 in 
vitro. (A) Fabrication and post-gelation loading of SDF-1a and/or FTY720 into albumin-
embedded Hep-N-PEG-DA gels (aHep-N). (B) SDF-1a and FTY720 are released over 7 
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days in vitro (n= 6 gels, 2 independent studies). (C) In vitro migration of primary murine 
bone marrow cells toward media conditioned by 24h of hydrogel release. *Indicates 
significance compared to all other groups (n=5, ANOVA, p<0.05). 
 
4.3.2. Dual release of SDF-1a and FTY720 from aHep-N-PEG-DA hydrogels 
promotes synergistic recruitment of leukocytes to the gel surface  
To measure the ability of aHep-N-PEG-DA gels to recruit endogenous cells in vivo, 
we utilized the dorsal skinfold window chamber model, a mouse model of excisional skin 
injury that enables intra-vital microscopic (IVM) assessment of host responses to 
biomaterial implants, including microvascular remodeling and associated recruitment of 
immune cells. aHep-N gels were implanted in wild-type C57Bl/6 mice for 3 days and 
explanted for analysis of cell recruitment to the implant-tissue interface. Brightfield 
microscopy of explanted gels reveals increased cell attachment to the surface of gels co-
releasing SDF-1α and FTY720 compared to either factor alone or unloaded control (data 
not shown). Cells were digested from the gel surface and characterized by flow cytometry. 
Recruitment of myeloid leukocytes (CD11b+) is greatest in response to co-delivery of 
FTY720 and SDF-1α in a pattern that indicates synergy between these two molecules 
(Figure 20a). Myeloid leukocytes (CD11b+) expressing the SDF-1α receptor (CXCR4) 
exhibit a similar, but non-significant, pattern of synergy in recruitment to the gel indicating 




Figure 20. Dual release of SDF-1a and FTY720 from aHep-N-PEG-DA hydrogels 
promotes synergistic recruitment of leukocytes to the gel surface. Gels were implanted 
in the dorsal skin window chamber for 3 days and explanted to evaluate cell association 
with the gel by flow cytometric analysis of (A) CD11b+ and (B) CD11b+CXCR4+ 
populations. (n= 5-6, ANOVA, *p<0.05) 
 
One day after implantation of either an unloaded Hep-N gel or an aHep-N gel co-
releasing FTY720 and SDF-1a into CX3CR1GFP/+ mice that allow the tracking of myeloid 
cells by GFP fluorescence, myeloid cells can be seen extravasating and migrating in the 
tissue adjacent to each gel (Figure 21a). Cells in the peri-implant region of the dual 
releasing gel had a greater displacement (Figure 21c) and directional migratory patterns 
compared to cells in the peri-implant region of the unloaded Hep-N gel (Figure 21e) 




Figure 21. Myeloid cells have greater directional motility around dual releasing gel. 
Myeloid cell movements were captured by intra vital microscopy of the dorsal window 
chamber in the CX3CR1GFP/+ transgenic mouse model one day after surgery and gel 
implantation. Myeloid cells (green) and vessels (red) were visible adjacent to the unloaded 
Hep-N-PEG-DA internal control gel (A) and the dual releasing aHep-N-PEG-DA SDF + 
FTY720 gel (B) in the same window chamber. Fifteen minute videos were acquired and 
cell tracking analysis was done in IMARIS software. Cell displacement (C) was enhanced 
in the region surrounding the experimental gel but not track length (D), suggesting that the 
cells are traveling in a straighter and more directed path (E). (n=2 mice, 2 regions of interest 
each, Mann-Whitney rank test, *p<0.05) 
 
4.3.3. Recruitment of mononuclear phagocyte subsets to tissue surrounding aHep-
N-PEG-DA gels 
To assess the immunophenotypes of recruited cells in the tissue surrounding each 
gel at day 3, a 4mm biopsy of dorsal tissue under the hydrogel was harvested and digested 
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for flow cytometric analysis. We have previously shown that non-classical monocytes 
(Ly6Clow) can be functionally distinguished from classical monocytes (Ly6Chigh) by higher 
surface expression of CXCR4 and S1PR3[6, 27]. In the present study, recruitment of non-
classical monocytes to the peri-implant tissue increased approximately 1.5-fold in response 
to delivery of either FTY720 or SDF-1α alone compared to animals implanted with the 
albumin containing control gel; however, co-delivery of FTY720 and SDF-1α did not 
significantly increase non-classical monocyte recruitment (Figure 22a). 
 
Figure 22. Recruitment of mononuclear phagocyte subsets to tissue surrounding 
aHep-N-PEG-DA gels. Tissue surrounding the hydrogel was analyzed 3 days after surgery 
and implantation for the immunophenotype of the recruited myeloid populations. (A) 
Either FTY720 or SDF-1a lead to an increase in non-classical monocyte 
(SSClowCD11b+Ly6Clow) recruitment to the gel as a percent of monocytes (SSClowCD11b+) 
(n=7-9, ANOVA, *p<0.05). (B) Dual release of FTY720 and SDF-1a significantly 
increased the presence of MerTK+CD64+ macrophages within the tissue as a percent of 
total cells (n=2-4, ANOVA of control, SDF-1, and FTY720/SDF-1 groups (FTY720 
excluded due to low sample size)). (C) Dual release similarly produced a trend of increased 
CD206+MerTK+CD64+ cells as a percent of total cells (n=2-4, ANOVA of control, SDF-











4.3.4. Dual release of SDF-1a and FTY720 increases abundance of M2-like 
macrophages 
Although both FTY720 and SDF-1a both individually increased recruitment of 
non-classical monocytes to the tissue adjacent to the hydrogel, the dual delivery gel did not 
exhibit the expected synergy of localized non-classical monocyte recruitment in these two 
chemotactic signaling axes. Previous studies suggest that non-classical monocytes 
recruited by FTY720 can differentiate into CD206+ wound healing macrophages within the 
injury niche[6]. We hypothesized that co-delivery of FTY720 and SDF-1α may support an 
accelerated monocyte-to-macrophage differentiation prior to the day 3 time point. In 
agreement with this hypothesis, co-release of FTY720 and SDF-1α increased the 
abundance of macrophages (MerTK+CD64+)[160, 161] in tissue surrounding the implanted 
biomaterial at day 3 (Figure 22b). The abundance of CD206+MerTK+CD64+ macrophages 
out of total cells at day 3 followed an increasing trend that paralleled the increase in total 
macrophages (Figure 22c).  
To further investigate this finding, we assessed in situ macrophage accumulation at 
later stages of repair by complementary microscopy techniques. The CX3CR1GFP/+ 
transgenic mouse model was selected to enable intra vital microscopic visualization of 
monocyte and macrophage populations based on GFP expression and cell morphology 
(Figure 23a)[41, 162]. Implantation of SDF-1α or dual-loaded gels in the CX3CR1gfp/+ 
mouse followed by confocal intra vital microscopy at day 6 revealed phenotypic 
differences in CX3CR1-GFP+ cell accumulation and morphology. The SDF-1α group had 
a higher proportion of rounded monocytes identified as CX3CR1-GFP+ (Figure 23b,d), 
whereas the dual release FTY720 + SDF-1α group was enriched in CX3CR1-GFPdim and 
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more elongated cells, features that are consistent with macrophage morphology[41] 
(Figure 23c,e).  
	
Figure 23. Dual release of SDF and FTY720 alters CX3CR1+ cell morphology. (A) 
CX3CR1-GFP/+ mice were fitted with a dorsal window chamber and after six days were 
injected (i.v.) with rhodamine-dextran to visualize perfused vessels. Confocal intravital 
imaging was then conducted in the region directly surrounding the hydrogel implant. (B, 
D) Tissue surrounding the SDF hydrogel had rounded CX3CR1-GFP+ cells surrounding 
the vasculature, while tissue surrounding the SDF + FTY720 hydrogel (C, E) had 
CX3CR1dim myeloid cells with elongated morphology consistent with macrophage 
phenotype. Scale bar 100µm. (representative images from n=3 ROI per gel) 
 
Whole-mount immunohistochemistry in wild-type C57Bl/6 mice at day 7 (Figure 
24a) revealed increased accumulation of CD68+CD206+ wound-healing macrophages in 
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the tissue surrounding gels co-releasing FTY720 + SDF-1α compared to either factor alone 
or control (Figure 24b). A higher proportion of CD68+ cells were also CD206+ in the dual 
treatment group (Figure 24c). Taken together, these results suggest that co-release of 
FTY720 and SDF-1α increases the early accumulation of CD68+CD206+ wound-healing 
macrophages compared to release of either factor alone. 
 
Figure 24. Dual release of SDF-1 and FTY720 increases abundance of CD206+ 
macrophages. (A) Whole-mount IHC and confocal microscopy shows accumulation of 
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CD68+ macrophages and CD206+CD68+ macrophages in tissue proximal to the gels at day 
7 (CD206, green; CD68, blue scale bar 100µm). (B-C) Quantification of CD206+CD68+ 
macrophages (n= 2-3 mice, 2-11 ROI each, ANOVA, *p<0.05). 
 
4.3.5. Dual release of SDF-1a and FTY720 synergistically increases the caliber 
of arterioles in tissue surrounding aHep-N-PEG-DA gels 
Mononuclear phagocytes serve a prominent regulatory role in arteriogenesis, which 
is critical to restoring perfusion to ischemic tissues[52, 129, 163]. To determine whether 
recruitment of pro-regenerative monocyte and macrophage populations by dual-loaded 
aHep-N gels is associated with enhanced arteriogenesis, we assessed the change in diameter 
of arterioles in the tissue surrounding aHep-N gels (Figure 25a). At day 3 during the acute 
phase of healing, FTY720-releasing gels cause a mean decrease in arteriolar diameter of -
21.7% while SDF-1α-releasing and co-releasing gels stimulate an increase of 20.1% and 
25.4%, respectively (Figure 25b). At day 7 during the later phase of healing, gels co-
releasing FTY720 + SDF-1α stimulated greater arteriolar diameter enlargement (Figure 
25c). In addition, the dual releasing gel produced a more densely packed network of 
microvasculature compared to an internal control Hep-N gel implanted in the same window 
chamber (Figure 25d,e,f). Taken together, these data demonstrate that co-release of 
FTY720 and SDF-1a from bi-functional aHep-N-PEG-DA gels provides a regenerative 
environment that supports the recruitment of CD206+ macrophages and a coordinate 
increase in vascular remodeling. 
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Figure 25. Dual release of SDF-1a and FTY720 synergistically increases the caliber 
of arterioles in tissue surrounding Hep-N-PEG-DA gels. (A) Brightfield intravital 
microscopy was used to measure enlargement of arterioles in the microcirculation 
surrounding implanted gels at day 3 (B) and day 7 (C) (ANOVA, *p<0.05, n=8-10 at day 
3, n=3-5 at day 7). (D-F) Whole mount immunofluorescent imaging of vessels 
(CD31+SMA+) surrounding unloaded control gels or aHep-N-FTY720 + SDF-1 gels within 
the same window chamber (n=3). 
 
4.4. Discussion 
The immune response to biomaterial implants critically regulates functional healing 
outcomes such as vascularization, tissue regeneration, transplant integration, and extent of 
 81 
fibrosis. By mimicking the presentation of natural inflammatory and regenerative signals, 
we have an opportunity to engineer the host-material interaction in the design of 
“immunologically smart” materials. Due to the complexity of the immune response, 
materials that can release multiple complementary factors are likely necessary to fine tune 
an engineered inflammatory response. We have previously shown that either SDF-1a or 
FTY720 released in a localized gradient from a biomaterial can support the enhanced 
recruitment of Ly6Clow non-classical monocytes and improved vascular remodeling. The 
inflammatory process is inherently complex and dynamic; tissues and infiltrating 
inflammatory cells integrate and respond to a multiplicity of signals which may be 
enhanced by localized release of multiple complementary therapeutic agents[23]. To move 
toward higher level of control of the local inflammatory environment, we have developed 
a bi-functional hydrogel that targets a mechanistic synergy between chemokine protein 
SDF-1α and the S1P signaling axis to enhance the recruitment and behavior of endogenous 
pro-regenerative leukocytes. Dual affinity aHep-N-PEG-DA hydrogels were engineered to 
achieve simultaneous in vivo release of SDF-1α and FTY720 with the goal of modulating 
local innate immunity to promote vascular remodeling that will support wound healing. 
We found that both SDF and FTY720 recruit Ly6Clow non-classical monocytes to the peri-
implant region; however, the combination of these two factors increases the number of 
CD206+ macrophages within the tissue suggesting a complex cellular response that can be 
achieved by combination of two signaling factors compared to either factor alone. 
To overcome the challenge of co-delivering two physiochemically distinct 
molecules—a hydrophilic protein and hydrophobic small molecule—we engineered a dual 
affinity hydrogel that exploits the growth factor affinity of heparin and lipid chaperone 
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activity of albumin. In the present study, albumin-embedded Hep-N-PEG-DA hydrogels 
released bioactive SDF-1α and FTY720 in vitro with approximately ~25% of the total SDF-
1α payload and ~85% of the FTY720 payload released by day 7. SDF-1α, loaded by 
charge-based interaction with a heparin derivative[116] covalently linked in the hydrogel, 
was delivered primarily in a burst release within the first 24-36 hours. Heparin-based 
growth factor loading provides an advantage of protecting the stability of the growth factor 
cargo under various conditions that may otherwise lead to denaturation or degradation[114, 
117]. To enable safe in vivo use of heparin and maintain its protective effect on growth 
factor cargo, we utilized a selectively -N desulfated heparin derivative (Hep-N) with 
reduced anticoagulant activity[115, 117]. In previous studies, we have demonstrated that 
this amount of SDF-1a released from aHep-N hydrogels in vivo stimulates a localized 
recruitment of Ly6Clow non-classical monocytes to the tissue surrounding the gel within 3 
days[27].  
To make the hydrogel bi-functional, albumin was encapsulated within the Hep-N 
hydrogels as a lipid carrier for co-delivery with protein cargo and a novel means to display 
bioactive lipids in a biomaterial context[159]. Chaperone proteins facilitate stability and 
transport of lipids within blood and tissue compartments. Albumin is one of the main 
chaperone proteins that reversibly binds S1P in the blood and has also been found to bind 
FTY720[159]. Nearly 35% of S1P is found in albumin-rich fractions of blood and 
approximately 65% is found in complex with ApoM high-density lipoprotein[164]. 
FTY720, which is loaded by affinity for albumin entrapped in the bulk gel, released with a 
burst and continued sustained release over 7 days for total release of approximately 85% 
of the loaded drug in vitro. The differences in cumulative release between SDF-1α and 
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FTY720 are likely due to the distinct means of loading within the aHep-N matrix. As we 
have observed previously with FTY720 released from PLGA polymer films, release of 
FTY720 alone from aHep-N gels increased recruitment of non-classical monocytes to the 
peri-implant niche suggesting in vivo bioactivity. This highly localized recruitment is a 
desirable feature in managing local versus off-target effects. While these gels were 
designed as 2mm disk gels to create a localized response within the 12mm dorsal skinfold 
window chamber injury, the size, shape, and loading could be altered to achieve a broader 
tissue coverage area to scale the response. Further, future iterations of the material could 
include degradable elements to extend the opportunity for cell infiltration into the material. 
Selective recruitment of Ly6Clow non-classical monocytes and CD206+ 
MerTK+CD64+ “wound-resolving” macrophages are associated with enhanced tissue 
repair[2, 6, 27, 57, 156]. The extent to which macrophage heterogeneity arises from 
inherent plasticity versus microenvironmental polarization (“on-site education”)[30], 
selective or sequential recruitment of monocyte subsets, or preferential survival of specific 
subtypes remains controversial due to the complex nature of the wound healing cascade in 
different injury contexts. Cells on the M2 end of the macrophage continuum are responsible 
for both stimulating the deposition of extracellular matrix and degrading/remodeling the 
matrix during wound healing; if left unchecked, these macrophages can contribute to 
pathologic fibrotic tissue[165]. A careful balance of the appropriate local cues must be 
struck to steer the inflammatory process towards healing and not chronic inflammatory 
fibrosis. Hydrogels were implanted in excisional skin wounds to evaluate synergy between 
S1PR3 and CXCR4 signaling axes with regard to pro-regenerative cell recruitment and 
microvascular remodeling. Dual release of SDF-1α and FTY720 synergistically increased 
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the recruitment of CD11b+ myeloid leukocytes and CXCR4+ cells to the implant-tissue 
interface relative to control or either factor alone supporting our hypothesis of functional 
synergy between these two pathways. Dual-loaded gels altered the early migratory 
behavior of monocytes that extravasated near the loaded implant, but not an unloaded 
control implant within the same window-chamber, indicating that release of these 
molecules affects the local behavior of monocytes in the tissue. Interestingly, within the 
peri-implant tissue, while both SDF-1a and FTY720 individually increased the proportion 
of Ly6Clow non-classical monocytes in the tissue, with dual release, we observed a 
synergistic increase in macrophages (MerTK+CD64+), but not monocytes. Dendritic cells 
were excluded from our analysis based on the findings that skin dendritic cells do not 
express high levels of CD64[161]. The finding of increased macrophage accumulation was 
further supported by the presence of myeloid cells with an elongated morphology 
consistent with macrophage phenotype in the CX3CR1GFP/+ mouse and also the presence 
of more CD206+ cells in whole mount immunohistochemistry of the peri-implant tissue. 
CD206 is most highly expressed on M2a macrophages, but may also be expressed at lower 
levels on M2c cells[23]. Detection of synergy in the macrophage pool but not their 
recruited monocyte precursors may be explained by enhanced differentiation. These 
findings suggest that the combination of these two factors in vivo produces a more complex 
synergy than we have previously observed in vitro or that has been described in the 
literature. While priming monocytes with FTY720 increases their migration toward SDF-
1a in vitro in an S1PR3 dependent manner[6], treating inflamed tissue with both SDF-1a 
and FTY720 causes an increase in cell recruitment and fate transition within the injury 
niche. We have previously shown that FTY720 released from PLGA thin films enhances 
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non-classical monocyte entrance into tissue from circulation as well as their differentiation 
into macrophages[6]. While the mechanism of this enhanced differentiation is 
incompletely understood, S1PR3 activation by FTY720 regulates reduced secretion of 
inflammatory cytokines from monocytes and increases in anti-inflammatory/pro-
regenerative protein secretion from endothelial cells[6]. Thus, FTY720 may serve as a 
tissue conditioning cue that provides on-site education to encourage pro-regenerative 
differentiation of recruited monocytes into macrophages and their polarization toward 
wound-resolving phenotypes. The precise mechanistic details of this phenomenon will 
require further investigation. 
Recruited leukocytes facilitate blood vessel remodeling during angiogenesis and 
arteriogenesis via strategic perivascular positioning, secretion of growth factors, and 
matrix-remodeling enzymes[43, 52, 55, 129, 166-168]. Expansion of the vascular network 
through formation of new vessels and increased caliber of existing vessels is crucial for 
supplying sufficient nutrients to promote tissue repair. Wound-resolving macrophages on 
the M2 end of the spectrum in particular are associated with enhanced vascular 
remodeling[26, 47, 52]. In the present study, dual release of SDF-1α and FTY720 
synergistically enhanced arteriolar structural enlargement in conjunction with greater 
accumulation of wound-resolving macrophages. While we cannot definitively say there is 
a causal relationship between the macrophages and vascular remodeling in this study, based 
on prior literature, we believe there is a strong link between the macrophage recruitment 
and increased vascular diameter and network density. Thus, the dual affinity aHep-N-PEG-
DA platform has potential to increase tissue perfusion and improve therapeutic outcomes 
after ischemia, trauma, and tissue transplantation. It remains unclear whether this 
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phenomenon is the result of increased total myeloid recruitment, increased differentiation 
of M2-like macrophages, or alterations to the behavior of the recruited cells[6]. Taken 
together, these results indicate that cooperativity between the SDF-1α/CXCR4 and 
FTY720/S1PR3 signaling axes can be exploited to localize pro-regenerative macrophages 
to sites of injury and enhance microvascular network remodeling.  
 
4.5. Materials and Methods 
4.5.1. Heparin modification 
N-desulfated heparin methacrylamide (Hep-N-MAm) was fabricated as described 
previously[27]. Briefly, heparin sodium salt (Sigma) was dissolved in dH2O at a 
concentration of 10 mg/mL and desalted using Dowex 50WX4 resin (mesh size 100-200, 
Sigma). Pyridine was added drop-wise to result in a pH of ~6, after which time excess 
pyridine was removed using a rotatory evaporator[114]. The solution was flash frozen and 
lyophilized to yield heparin pyridinium salt. Next, heparin pyridinium salt was dissolved 
in 90% DMSO/10% ddH2O (v/v) at a concentration of 1 mg/mL, mixed for 2h at 50°C 
using a rotary evaporator, cooled and precipitated with 95% ethanol (VWR) saturated with 
sodium acetate (VWR). The precipitate was centrifuged, collected, and dissolved in dH2O 
and this solution was dialyzed for 3 days followed by lyophilization to yield N-desulfated 
heparin. Finally, the product was functionalized with methacrylamide groups with an 8.0 
molar excess of of N-(3-aminopropyl) methacrylamide hydrochloride (APMAm, 
Polysciences), N-hydroxysuccinimide (NHS, Acros Organics) and N-3-
dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDC, Sigma) at an acidic 
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pH. After functionalization, Hep-N-MAm was dialyzed, lyophilized, and stored at -20°C 
until use. Proton nuclear magnetic resonance (1H NMR) was performed to determine the 
degree of methacrylamide functionalization whereby Hep-N-MAm was dissolved in 
deuterated water (10 mg/mL) and 1H NMR spectra were recorded on a Bruker Avanace III 
400 spectrometer at 400 MHz. 
 
4.5.2. Hydrogel fabrication  
As described previously, PEGDA and Hep-N-MAm were UV sterilized, combined 
in a 9:1 PEGDA:Hep-N-MAm ratio, and then added to a sterile phosphate buffered saline 
(PBS) solution comprised of GMP-quality bovine serum albumin (BSA, Sigma), 
ammonium persulfate (APS, 0.018M, Sigma), and N,N,N`,N`-tetramethylethylenediamine 
(TEMED, 0.018M, Sigma). Final concentrations of components in the hydrogel precursor 
solution were as follows: PEGDA, 10.0% w/v; Hep-N-MAm, 1.1% w/v; BSA, 5.6% w/v; 
APS, 0.41% w/v; and TEMED, 0.21% w/v.” The hydrogel precursor solution was pipetted 
between two sterile glass slides with an inner clearance of 0.5 mm, allowed to gel for 10 
minutes at room temperature, and then punched with 2mm diameter biopsy punches 
(Miltex) to form gels of 0.5 mm thickness and 2 mm diameter. 
 
4.5.3. SDF-1α/FTY720 loading and release in vitro 
Following fabrication, gels were placed in ultra-low binding 24-well plates and 
rinsed with PBS for 3h. For FTY720 only gels, a 10 µL droplet containing 2.38 x 10-8 
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moles of either FTY720 (Cayman Chemical) or fluorescent 7-Nitrobenz-2-oxa-1,3-diazol-
4-yl-FTY720 (Cayman Chemical) was added to the top of each gel and the gels were 
incubated overnight at 4˚C.  After loading, gels were rinsed for 3h at room temperature 
with 500 µL PBS. For SDF-1α only gels, PBS was removed and a 10 µL droplet of SDF-
1α (0.1 µg; PeproTech) was added to each gel followed by incubation overnight at 4˚C.  
For dual-loaded gels, FTY720 was loaded overnight first, followed by SDF-1α. (For parity 
in sample treatment, in gels with either FTY720 or SDF-1α only, the samples would 
undergo both overnight incubations, but with a 10 µL droplet of PBS in place of the drug 
that was not being loaded.)  
After loading, the wells were filled with 500µL of PBS and incubated at 37°C for 
the release study.  At each timepoint, PBS was exchanged and stored at -80ºC for 
subsequent analysis. The concentration of SDF-1α in supernatant was quantified using a 
Mouse CXCL12/SDF-1α Quantikine ELISA Kit (R&D Systems) and the concentration of 
7-Nitrobenz-2-oxa-1,3-diazol-4-yl-FTY720 was quantified using a fluorescence plate 
reader with λex = 485nm and λem = 515nm. Two batches of Hep-N-MAm were required to 
complete all studies, and therefore FTY720 and SDF-1α release from hydrogels made with 
both Hep-N-MAm batches were averaged to obtain final release curves (n = 6 hydrogels per 
group across 2 batches of Hep-N-MAm). 
 
4.5.4. In vitro migration 
Bioactivity of released SDF-1α/FTY720 was assayed in vitro as described 
previously. Briefly, albumin-embedded gels loaded with FTY720 and SDF-1α (aHep-N-
FTY+SDF), SDF-1α alone (aHep-N-SDF), or neither factor (aHep-N) were incubated with 
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650µL of Iscove’s Modified Dulbecco’s Medium (Fisher) containing 0.5% fatty acid-free 
bovine serum albumin (Fisher) for 24h at 37°C. A transwell assay was assembled by 
transferring hydrogel-conditioned media to the chamber below a 5µm pore size membrane, 
and seeding 4x105 cells from C57BL/6 mouse bone marrow aspirate on top. After 4h of 
migration at 37°C and 5% CO2, migrated cells were stained with DRAQ5 dye according 
to manufacturer’s protocol (Cell Signaling Technologies). Relative migration was 
quantified by fluorescence intensity using an Odyssey CLx Infrared Imaging System (LI-
COR Biosciences). Statistical analysis was performed using one-way ANOVA, Geisser-
Greenhouse correction for non-sphericity, and Tukey post-hoc multiple comparisons test 
(n=5). 
 
4.5.5. Dorsal skinfold window chamber and hydrogel implantation 
Male C57BL/6 mice aged 8-12 weeks of age were anesthetized by i.p. injection of 
a mixture of ketamine (100mg/kg) and xylazine (10mg/kg) in sterile 0.9% saline or by 
inhaled isoflurane and surgically fitted with sterile dorsal skinfold window chambers (APJ 
Trading Co.) as previously described[6, 53, 151, 152]. Prior to surgery, dorsal skin was 
shaved, depilated, and sterilized via triplet washes of 70% ethanol and chlorhexidine. A 
double-layered skin fold was elevated off the back of the mouse and the back side of the 
titanium window chamber frame was surgically fixed to the underside of the skinfold. 
Surgical microscissors were used to remove the epidermis and dermis from the top-side of 
the skinfold in a circular area (diameter = 12mm) to reveal the vasculature underlying the 
reticular dermis. Exposed tissue was kept hydrated with sterile saline. The front side of the 
titanium frame was then mounted on the top of the skin and attached to its underlying 
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counterpart. The dorsal skin was sutured to the titanium frame, and mice were implanted 
with one Hep-N internal control hydrogel and one aHep-N experimental hydrogel (unloaded 
or loaded albumin-containing gel with SDF-1α, FTY720, or both factors) placed on 
opposite sides of the window. The exposed tissue was then overlaid with a protective sterile 
glass coverslip. Mice were allowed to recover in heated cages and administered sustained 
release buprenorphine via i.p. injection as a postoperative analgesic. All mice received a 
standard laboratory diet and water ad libitum throughout the course of the experiment. 
 
4.5.6. Flow cytometry and identification of immunophenotypes 
To measure the recruitment of cells to tissue surrounding the hydrogels, the dorsal 
tissue circumscribing the gel position was collected and digested with 1mg/mL collagenase 
IA (Sigma) in Krebs-Ringers solution at 37°C, and further disaggregated with a cell strainer 
and pestle to create a single cell suspension. To examine cells at the hydrogel interface, 
cells were removed from the hydrogel surface by incubation with trypsin for 10min at 37°C 
and combined with a fixed volume of flow cytometry counting beads for quantification 
(CountBright Absolute Counting Beads, Life Technologies). Immuno-staining and flow 
cytometry analyses were performed according to standard procedures and analyzed on a 
FACS-AriaIIIu flow cytometer (BD Biosciences). The following antibodies were used for 
cell phenotyping: APC/Cy7- or BV510-conjugated anti-CD11b (BioLegend, M1/70), 
APC- or BV421-conjugated anti-Ly-6C (BioLegend, HK1.4), PE- or PerCP/Cy5.5-
conjugated anti-CXCR4 (eBiosciences, 2B11), PE-conjugated anti-MerTK (R&D 
Systems, 108928), BV711-conjugated anti-CD64 (BioLegend, X54-5/7.1), and BV605-
conjugated anti-CD206 (BioLegend, C068C2). Monocyte populations were defined as 
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CD11b+SSClowLy-6Chigh/low and were confirmed to be Ly-6G- (BioLegend, 1A8). 
Macrophages were identified with high fidelity as MerTK+CD64+ cells[160] which 
excludes dendritic cells[161]. Further confirming macrophage identity of the 
MerTK+CD64+ cells, nearly all cells identified as macrophages expressed F4/80 (data not 
shown). Statistical analysis in Figure 20 and Figure 22 was conducted using one-way 
ANOVA, Geisser-Greenhouse correction for non-sphericity, and Tukey post-hoc multiple 
comparisons test. The number of replicates in are as follows: Figure 20, n=5-6; Figure 
22a, n=7-9; Figure 22b,c, n=2-4. 
 
4.5.7. Confocal intra-vital microscopy of CX3CR1+ macrophages 
Male heterozygous B6.129P-Cx3cr1tm1Litt/J (CX3CR1-EGFP) mice were utilized 
to visualize monocytes and macrophages in live mice based on their selective surface 
expression of CX3CR1[6, 27, 34]. Confocal intra-vital microscopy was performed on day 
1 or day 6 after surgery and gel implantation. To label perfused vasculature, mice were 
anesthetized with isoflurane gas and given a retro-orbital injection of high molecular 
weight TRITC-conjugated dextran (2 MDa; Life Technologies). For subsequent 
microscopy, the mouse was secured to the microscope stage in a custom adapter, the glass 
window was removed, and dorsal tissue was irrigated with sterile saline. Z-stack images 
were acquired immediately proximal to the gel using a 20X water immersion objective 
(NA=1.0) on a Zeiss LSM710 NLO microscope. For 3D analysis in Imaris (Bitplane), time-
lapse images (period=30s, duration=15min) were acquired to visualize immune cell 
migration in the close surrounding tissue. Cells expressing CX3CR1-GFP were identified 
in Imaris using the surface tool. CX3CR1+ surfaces were identified by smoothing with a 
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2µm grain size and an automatic threshold on absolute intensity. Touching objects were 
split using a seed points diameter of 10µm. Vessels were identified in Imaris by drawing a 
surface on the TRITC-dextran fluorescent channel with a 3µm grain size, manually-
selected threshold value (determined based on each image), and manually-selected volume 
filter to remove small debris. The automatic cell tracking feature was selected, and the 
following metrics were exported for statistical analysis: track displacement, track length, 
and track straightness. For statistical analysis of cell migration metrics in figure 3, Mann-
Whitney rank test was performed on the distribution comprised of all cells analyzed across 
2 mice per group and 2 ROI per mouse (FTY720+SDF-1, n=3095; internal control, 
n=2119). 
 
4.5.8. Whole-mount IHC and confocal microscopy of recruited macrophages  
On day 7 after surgery and gel implantation, mouse vasculature was perfused with 
warm 0.9% saline and then 4% PFA until tissues were fixed. Dorsal tissue was explanted 
and drop-fixed in 4% PFA for 10min, permeabilized with 0.2% saponin in PBS for 16-24h 
at 4°C, blocked with 10% mouse serum in PBS for 16-24h, and stained with combinations 
of the following monoclonal antibodies diluted into a solution of 0.5% BSA, 5% mouse 
serum, and 0.1% saponin in PBS: Cy3-conjugated anti-⍺-smooth muscle actin (αSMA, 
1:300, Sigma), AF594-conjugated anti-CD31 (1:100, BioLegend), AF647-conjugated anti-
CD68 (1:200, AbD Serotec), and AF488-conjugated anti-CD206 (1:200, AbD Serotec). 
Images of macrophage accumulation in dorsal tissue were acquired as 3-dimensional z-
stacks in confocal mode using a Zeiss LSM710 NLO microscope at 20X magnification. To 
quantify the number of CD68+CD206+ macrophages per unit area, Imaris (Bitplane) 
 93 
software was used. Surfaces were created in the CD68 and CD206 channels independently, 
and the number of CD68+ surfaces overlapped by CD206+ surfaces were counted. In 
Figure 25, cell density is reported for n=2-11 regions of interest per group across 2-3 
animals per group. 
 
4.5.9. Brightfield intra-vital microscopy and analysis of arteriolar diameter 
Immediately following surgery and on day 3, mice were maintained under 
isoflurane anesthesia, the glass window was removed, and dorsal tissue was flooded with 
1mM adenosine in Ringer’s solution to maximally dilate all vessels and maintain tissue 
hydration. The mouse was then mounted to a custom microscope stage mount and a tile 
scan of the entire window was acquired noninvasively at 5X magnification on a Zeiss 
Imager.D2 microscope with AxioCam MRc 5 color digital camera (Carl Zeiss). To 
measure changes in the diameter of arterioles, arteriole–venule pairs were identified within 
a 3mm radius of the center of each gel. Arterioles and venules were identified on the basis 
of size and morphology at day 0. Internal diameters based on blood column width in 
brightfield images were measured using Zen Blue (Zeiss) and recorded longitudinally for 
each vessel segment on day 0 and 3. Quantification of arteriolar diameter was restricted to 
the microvasculature by analyzing arterioles with diameters <40µm on day 0[27, 129]. 
Analysis was limited to arterioles visible at both time points (1-7 arterioles/gel). 
 
4.5.10. Statistical analysis 
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Data are presented as mean ± standard error of the mean (SEM).  All statistical 
analysis was executed in GraphPad Prism software. Statistical tests are reported in the 
methods and legends associated with each figure. Unless otherwise noted, p<0.05 was 
considered statistically significant.  
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5. RELATIONSHIP BETWEEN IMMUNE CELL INFILTRATION 
AND ROTATOR CUFF MUSCLE DEGENERATION3 
5.1. Introduction 
Full-thickness rotator cuff tears (RCTs) are present in more than 20% of the 
population[169]. RCTs increase in frequency and severity with age and cause significant 
pain and functional deficiency[170-174]. RCT causes degeneration of the associated 
muscles, a process which includes muscle retraction and atrophy, fatty infiltration, and 
fibrosis. Muscle degeneration is a strong predictor of patient morbidities such as pain, 
functional deficiency, and post-surgical tear recurrence, and is not reversed by tendon 
repair[175, 176]. Thus, prevention or reversal of muscle degeneration due to RCT is a 
major unmet clinical need. Identification of molecular and cellular targets for therapeutic 
intervention requires elucidating the underlying pathobiology of RC muscle degeneration. 
Evidence from RCT and chronic muscle pathologies suggests that inflammation, 
particularly mononuclear phagocyte (MP) infiltration, contributes to muscle degeneration. 
Pro-inflammatory cytokines such as TNFα and IL-6 stimulate apoptosis of myocytes and 
catabolism of intramyocellular proteins[64, 65], thus causing muscle atrophy in cancer 
cachexia and autoimmune disorders. Classical “pro-inflammatory” subpopulations of 
mononuclear phagocytes secrete more pro-inflammatory cytokines compared to non-
                                                
3 Adapted from: J.R. Krieger, L.E. Tellier, M.T. Ollukaren, J.S. Temenoff, E.A. Botchwey, 
Quantitative Analysis of Immune Cell Subset Infiltration of Supraspinatus Muscle After 
Severe Rotator Cuff Injury, Regenerative Engineering and Translational Medicine  (2017) 
1-12. Reprinted with permission from Springer Nature. 
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classical alternatively-activated subpopulations[8, 11, 22-24], suggesting that 
intramuscular infiltration of classical subtypes may promote chronic muscle degeneration. 
Indeed, in the mdx mouse model of Duchenne muscular dystrophy, chronic muscle 
degeneration is in part caused by the classical pro-inflammatory Ly6Chi subset of 
circulating monocytes (MO)[66]. Human and rodent muscles undergoing fatty 
degeneration after RCT show dramatic co-localization of fat-rich regions with 
macrophages (MF) that contain intracellular lipid droplets[67, 68]. Rotator cuff muscle 
degeneration is exacerbated by administration of lysophosphatidic acid, whereby MF 
accumulation and TNFα expression are increased[69]. Taken together, these studies 
suggest that pro-inflammatory mononuclear phagocytes promote chronic muscle 
degeneration.  
Because MP are comprised of highly heterogeneous subpopulations that exert 
divergent effects on injured tissue during pathogenesis and regeneration, understanding RC 
muscle inflammation at the subpopulation level is critical for identifying therapeutic 
targets. The spectrum of MF phenotypes is commonly simplified into two primary 
categories: classically-activated “M1” and non-classical or alternatively-activated “M2”, 
of which multiple subtypes have been described[11]. Accumulation of MF within injured 
adult skeletal muscle is primarily driven by recruitment of circulating MO rather than 
expansion of tissue-resident MF[1]. MO circulate as functionally distinct subsets in both 
mouse and human blood. Classical MO are characterized by Ly6ChiCX3CR1lo expression 
in mice (CD14hiCD16- in human), whereas non-classical MO are Ly6CloCX3CR1hi in mice 
(CD14+CD16+ in human)[34]. Ly6Chi classical MO predominate the acute phases of injury, 
secrete inflammatory cytokines such as IL-6, iNOS, and TNFα[29], and produce high 
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levels of matrix metalloproteinases and cathepsins[8], whereas Ly6Clo MO predominate in 
later phase inflammation, promote angiogenesis and matrix deposition, and secrete higher 
levels of VEGF, TGFβ, and IL-10 and lower levels of TNFα and IL-1β[1, 8, 30]. MO 
recruitment is required for natural repair; multiple studies show that depletion of circulating 
MO causes incomplete and fibrotic healing of skeletal muscle after toxin-induced injury[1, 
59, 60]. In early stages after acute muscle injury, infiltrating Ly6Chi MO ingest debris and 
induce proliferation of myosatellite mononuclear progenitor (satellite) cells[1]. In later 
stages, Ly6Clo MO and M2 MF subsets promote satellite cell myogenic differentiation and 
fusion to expand myotubes, and secrete insulin-like growth factor-1 (IGF-1) required for 
muscle regeneration[63].  
Given that different subpopulations of MP exert distinct effects on skeletal muscle, 
the present study seeks to investigate the phenotypic distribution and causal role of 
inflammatory cells in supraspinatus (SS) degeneration after severe RCT in a mouse model. 
As in Aims 1 and 2, biomaterial-mediated local delivery of SDF-1 or FTY720 is evaluated 
for its ability to modulate inflammation and protect against degeneration. 
 
5.2. Results 
5.2.1. Mononuclear phagocyte recruitment to supraspinatus muscle after severe 
rotator cuff injury  
To quantify subpopulations of inflammatory cells within the SS muscle after 
massive RC injury, SS muscles were harvested 7 days after injury and analyzed by flow 
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cytometry. MP were identified according to the following surface marker expression: MF 
= MerTK+ CD64+; dendritic cell (DC) = NOT(MerTK+ CD64+) CD11c+; MO = 
NOT(MerTK+ CD64+) CD11c- CD11b+ SSClo (Figure 26a)[177]. MP count is 3.9x104 
cells/g in the tenotomy (TT) group and 8.7x104 cells/g in the tenotomy plus denervation 
(TT+DN) group, which represent 3.2-fold and 3.9-fold increases from respective uninjured 
contralateral muscles (Figure 26b). MP count is 2.2-fold greater in TT+DN than TT 
(Figure 26b). MF count is 3.0x104 cells/g in the TT+DN group, increasing 6.3-fold 
compared to contralateral (Figure 26c). MO count is 1.0x104 in TT and 2.3x104 in TT+DN, 
representing 2.4-fold and 2.6-fold increases compared to contralateral controls (Figure 
26d). MO count is 2.3-fold greater in TT+DN than TT (Figure 26d). DC count in the 
TT+DN group is 3.9-fold higher than contralateral and 2.1-fold higher than TT (Figure 
26e). The frequency of DC, MF, and MO populations is 1.7%, 1.2%, and 1.1% in TT, 
respectively, compared to 2.5%, 2.1%, and 1.6% in TT+DN (Figure 26f). Overall, results 
indicate that injury causes dramatic accumulation of MO, MF, and DC. 
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Figure 26. Mononuclear phagocyte accumulation in supraspinatus muscle 7 days 
after rotator cuff injury. (A) Flow cytometry gating scheme to identify populations of 
mononuclear phagocytes after pre-gating for single cells. Mononuclear phagocyte count 
(B) is calculated as the sum of macrophages (C), monocytes (D), and dendritic cells (E) 
normalized to muscle mass. (F) Frequency of each mononuclear phagocyte population out 
of total cells. Closed circles represent the injured side; open circles, uninjured contralateral 
side. Statistical comparisons are conducted by repeated measures two-way ANOVA 
followed by Sidak multiple comparisons test (TT, n=5; TT+DN, n=4). *P<0.05, **P<0.01, 
***P<0.001 comparing injury side to contralateral side. ^P<0.05, ^^P<0.01, ^^^P<0.001 
comparing TT+DN to TT. 
 
5.2.2. Non-classical subpopulations predominate mononuclear phagocyte 
infiltration 
M1-like and M2-like subpopulations of MF were identified by surface expression 
of CCR7 and CD206, respectively (Figure 27a), as per Spiller et al.[23]. TT increases the 
frequency of CD206+ cells within the MF pool from 29.3% to 59.9%; TT+DN, from 39.8% 
to 74.7% (Figure 27b). CD206+ frequency is higher in TT+DN compared to TT (Figure 






























































































77.7% to 59.6%; TT+DN, from 82.7% to 64.2% (Figure 27c). Thus, SS muscle is biased 
toward M1-like MF without injury, and toward M2-like MF after TT and TT+DN. The 
TT+DN group has the highest counts of both CD206+ MF and CCR7+ MF compared to 
TT and contralateral (Figure 27d). Increased CCR7+ MF count despite decreased CCR7+ 
MF frequency in the MF pool is explained by the larger overall pool of MF in the TT+DN 
group. 
 
Figure 27. Macrophage subpopulations. (A) Flow cytometry gating scheme to identify 
CD206+ and CCR7+ macrophages. The fractions of CD206+ (B) and CCR7+ (C) cells 
within the macrophage pool are affected by rotator cuff injury. TT+DN injury increases 
the number of CD206+ and CCR7+ macrophages per gram of muscle (D). Closed circles 
represent the injured side; open circles, uninjured contralateral side. Statistical comparisons 
are conducted by repeated measures two-way ANOVA followed by Sidak multiple 
comparisons test (TT, n=5; TT+DN, n=4). *P<0.05, **P<0.01 comparing injured side to 



















































































MO subpopulations are discriminated by surface expression of Ly6C (Figure 
28a)[8, 34]. TT+DN significantly increases the frequency of non-classical Ly6Clo (Figure 
28b) and decreases the frequency of classical Ly6Chi (Figure 28c) cells within the MO 
pool compared to contralateral, whereas TT has no significant effect on Ly6Clo/Ly6Chi 
frequency. Consequently, TT+DN increases the absolute count of both Ly6Clo and Ly6Chi 
compared to TT and contralateral (Figure 28d). TT increases Ly6Clo count compared to 
contralateral, owing increased overall MO count (Figure 28d).  
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***P<0.001, ****P<0.0001 comparing injury side to contralateral side. ^P<0.05, 
^^P<0.01, ^^^P<0.001 comparing TT+DN to TT. 
 
5.2.3. Neutrophil and T lymphocyte recruitment 
Neutrophil and T lymphocyte infiltration is also quantified (Figure 29). 
Neutrophils (Ly6G+) are present in low abundance (6000 cells/g) relative to other 
inflammatory cell types measured. Neither injury affects neutrophil count (Figure 29b) 
but TT increases the frequency of neutrophils out of total cells compared to TT+DN 
(Figure 29c). T lymphocyte count is unaffected by either injury (Figure 29d), but the 
frequency of T lymphocytes decreases due to TT (Figure 29e). Helper T lymphocyte (TH; 
CD4+CD3+) and regulatory T lymphocyte (Treg; CD25+CD4+CD3+) counts and frequency 
out of total cells do not change due to injury (Figure 29f,g,i,j). Injury enriches the T 
lymphocyte pool in TH cells, as evidenced by TT increasing the TH frequency within the T 
lymphocyte pool from 2.8% to 7.5% and TT+DN increasing the frequency from 3.2% to 
4.9% relative to controls (Figure 29h). The TH frequency within the T lymphocyte pool is 
higher in TT compared to TT+DN (Figure 29h). Neither injury enriches the TH pool in 
Treg cells (Figure 29i). The Treg frequency within the T lymphocyte pool is higher in TT 




Figure 29. Quantification of neutrophil and T lymphocyte populations. (A) Flow 
cytometry gating scheme to identify neutrophils (Ly6G+), T lymphocytes (CD3+), TH 
(CD4+CD3+), and Treg (CD25+CD4+CD3+). Cell count per gram of muscle of neutrophils 
(B), T lymphocytes (D), TH (F), and Treg (I) is not significantly affected by injury. TT 
increases neutrophil frequency out of total cells compared to TT+DN (C). TT decreases T 
lymphocyte frequency out of total cells compared to uninjured contralateral (E). Neither 
injury affects TH (G) or Treg (J) frequency out of total cells. The fractions of TH (H) and 
Treg (K) within the T lymphocyte pool are increased by injury. The fraction of Treg within 
the TH pool is unaffected by injury (L). Statistical comparisons are conducted by repeated 
measures two-way ANOVA followed by Sidak multiple comparisons test (TT, n=5; 
TT+DN, n=4). *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 comparing injured side to 
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5.2.4. Multivariate analysis of immune cell infiltration 
To describe the inflammatory profile in a reduced-dimensionality model, 
unsupervised principal component (PC) analysis was performed on a set of 11 flow 
cytometric measurements. Injured versus contralateral muscles are discriminated along 
PC1, and TT versus TT+DN muscles are discriminated along PC2 (Figure 30b). The x-
axes of the loadings (Figure 30a) and scores (Figure 30b) plots show that injury is 
described by increased MO, MF, DC, Ly6Clo MO, CD206+ MF, TH, and Treg, and 
decreased CCR7+ MF, T lymphocytes, and wet muscle mass. The y-axes of the loadings 
and scores plots show that TT+DN is discriminated from TT by increased MO, MF, DC, 
CD206+ MF, and T lymphocytes, and decreased TH, Treg, and neutrophils. 
 
Figure 30. Unsupervised principal component analysis of flow cytometry 
quantification. (A) Loadings (weight coefficients) plot of the 11 input variables in the 
reduced principal component space. Input variables are: muscle mass, MF (% of cells), 
MO (% of cells), DC (% of cells), T lymphocyte (% of cells), neutrophil (% of cells), 
CD206+ (% of MF), CCR7+ (% of MF), Ly6Clo (% of MO), TH (CD4+CD3+ % of CD3+), 
and Treg (CD25+CD4+CD3+ % of CD4+CD3+). (B) Injury conditions are separated by the 
model in the scores plot (TT, n=5; TT+DN, n=4). Quality-of-fit metrics are provided in 
Methods. 
 






















































Pro-regenerative cytokines are secreted after injury 
 To assess whether predominance of non-classical subpopulations is associated with 
a pro-regenerative cytokine and growth factor milieu, 22-plex quantitative immunoassay 
was performed on SS muscle lysate at day 7. TT+DN injury significantly affected the 
production of 6 of the 22 proteins analyzed, increasing the production of IL-10, IL-33, 
SDF-1α, IGF-1, FGF-basic, and Dkk-1 compared to uninjured contralateral controls 
(Figure 31). 
 
Figure 31. Cytokine and growth factor production in supraspinatus after RCT. 
Cytokines and growth factors involved in immune cell polarization and muscle 
degeneration and regeneration were quantified via Luminex 22-plex immunoassay. 
TT+DN injury increases production of IL-10 (A), IL-33 (B), SDF-1α (C), IGF-1 (D), FGF-
basic (E), and Dkk-1 (F) compared to uninjured contralateral control (n=5, *P<0.05, 
**P<0.01, paired t-test). 
 


















































































































Intravenous administration of liposomal clodronate is an experimental tool used to 
deplete circulating MO[178, 179].  Liposomal clodronate causes complete depletion of 
blood MO within 6 h followed by recovery of the Ly6Chi and Ly6Clo populations at 2 and 
7 days, respectively[178]. The present study investigates the contribution of circulating 
MO to SS atrophy by administering liposomal clodronate (clod-lip) or saline control every 
2-3 days upon combined tenotomy and denervation injury (Figure 32a). Clod-lip decreases 
wet muscle mass compared to uninjured contralateral control at 21 days (mean: 29.0 vs. 
41.8 mg), whereas saline control has no effect (mean: 38.5 vs. 41.5 mg) (Figure 32b). 
Clod-lip causes greater percent decrease in wet mass between injured and uninjured 
contralateral muscles compared to saline control (Figure 32c). Quantification of myofiber 
cross-sectional area (CSA) is a complementary approach to assess muscle atrophy and is 
accomplished using immunohistochemistry (IHC) to visualize collagen IV in the myofiber 
basement membrane (Figure 32d). Saline control shows no difference in myofiber CSA 
between injured and uninjured contralateral muscles (median: 607 vs. 655 µm2) (Figure 
32e). Lack of atrophy at 21 days in the saline control group is consistent with literature 
indicating that mouse SS degeneration is detected at 6-12 weeks[69, 180-182]. Notably, 
clod-lip causes decreased CSA compared to both uninjured contralateral (median: 507 vs. 
641 µm2) (Figure 32f) and saline controls (Figure 32g). Taken together, these results 
indicate that depletion of circulating MO via liposomal clodronate accelerates SS atrophy 
after severe RC injury.  
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Figure 32. Liposomal clodronate accelerates muscle atrophy. Liposomal clodronate is 
delivered intravenously at 2-3 day intervals following TT+DN injury (A).  To assess 
muscle atrophy, supraspinatus mass (B) and percent change in mass between injured and 
uninjured contralateral supraspinatus (C) are measured at day 21 (Saline, n=4; Clod-lip, 
n=5). Myofiber cross-sectional area is visualized by anti-collagen IV IHC (D) and 
quantified using ImageJ (E-G) (n=964 across 4 animals per group). Statistical comparisons 
are conducted by two-way ANOVA with Sidak post-hoc test (B), t-test (C), and Mann-
Whitney rank test (E-G). ^P<0.05, *P<0.05, ***P<0.001, ****P<0.0001. Scale bar: 100 
µm. 
 
5.2.6. Local delivery of SDF-1 via Hep-N microparticles increases recruitment of 
dual polarized MF 
 To investigate MP infiltration in response to local delivery of SDF-1, we employed 













































































































































































































































hydrogel platform, enabling injection into the SS. Microparticles released human SDF-1 
by approximately 24 h in vitro (Figure 33a,b). Microparticles were injected into the 
supraspinatus during surgery and immune cell infiltration was assessed at day 7 by flow 
cytometry. Human SDF-1 decreased the proportion of CD206+CCR7+ “dual polarized” 
MF within the MF pool compared to FTY720, unloaded MP, and untreated control 
(Figure 33a,b). 
 
Figure 33. SDF-1-releasing aHep-N microparticle delivery to the supraspinatus. (A) 
Release kinetics of human SDF-1 from microparticles. (B) SDF-1-loaded microparticle 
delivery at the time of surgery decreases the proportion of CD206+CCR7+ “dual 
polarized” macrophages at day 7 as measured by flow cytometry. *P<0.05, **P<0.001 by 
two-way ANOVA and post-hoc multiple comparisons test (n=3-4). 
 
5.2.7. Local, sustained delivery of FTY720 via PLGA microparticles 
Although SDF-1-releasing Hep-N microparticles exhibited immunomodulatory 
activity by decreasing the frequency of dual polarized MF, it is unclear whether this initial 
outcome is desirable toward the goal of inhibiting degeneration and/or enhancing 
regeneration of SS muscle. Because FTY720 affects both the recruitment and cytokine 

















































elaboration of MO[6], and because sustained release of FTY720 over several weeks can be 
achieved using PLGA microparticle carriers[183], we next attempted therapeutic 
immunomodulation using local delivery of FTY720-loaded PLGA microparticles. To 
achieve sustained local delivery of FTY720 during the progression of immune cell 
infiltration, 50:50 PLGA microparticles encapsulating FTY720 (total dose = 10 µg, 
drug:polymer ratio = 1:150) were injected into SS muscle at the time of surgery. PLGA 
microparticles release FTY720 in vitro with an initial burst followed by relatively linear 
release (Figure 34b). Microparticle-mediated delivery of 10 µg FTY720 does not affect 
MP count, T lymphocyte count, or TH/Treg count at day 7; however, the frequency of Treg 
cells in the TH and T lymphocyte populations is decreased in the FTY720 microparticle 
group compared to unloaded PLGA microparticles and vehicle control (Figure 34c,d).  
 
Figure 34. Effect of FTY720-releasing PLGA microparticles at acute day 7 time point. 
(A) Light microscopy image of PLGA microparticles (scale bar = 100 µm). (B) FTY720 























































































was 10 µg. FTY720 release decreases the frequency of Treg cells within the T lymphocyte 
(C) and helper T lymphocyte (D) populations in SS muscle at day 7 (n=4-5, two-way 
ANOVA with repeated measures). *P<0.05, ***P<0.001, ^P<0.05, ^^P<0.01, 
^^^^P<0.0001. 
 
Contrary to the initial hypothesis, FTY720 microparticles do not affect levels of 
key cytokines and growth factors at day 7 compared to PLGA and untreated controls, as 
determined by a 22-plex protein immunoassay. Microparticle-mediated delivery of 1.1 µg 
FTY720 does not significantly affect SS wet mass at week 9 compared to untreated control 
and PLGA MPs; however, PLGA MPs significantly decrease mass compared to untreated 
control (Figure 35b). Similarly, PLGA MPs increase accumulation of CD68+ MF and 
CD206+CD68+ M2-like MF at week 9 compared to untreated control, whereas FTY720 
release returns CD68+ and CD206+CD68+ counts to the same level as untreated control 
(Figure 35c-f). Decrease in muscle mass did not correlate strongly with CD206+CD68+ 
count (r2 = 0.18, (Figure 35g), and the slope of the regression line did not significantly 
differ from zero. 
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Figure 35. Effect of FTY720-releasing PLGA microparticles at chronic week 9 time 
point. (A) FTY720 release kinetics in vitro from PLGA (1:70) microparticles. (B) PLGA 
microparticles decrease the percent change in wet mass between injured SS and uninjured 
contralateral SS (B). Macrophage (C), CD206+ macrophage (D), and CD206- macrophage 
(E) counts as determined by cross-sectional IHC (F; scale bar = 20 µm). Change in SS 
mass does not negatively correlate with CD206+ macrophages (G; r2 = 0.18). *P<0.05 by 
ANOVA (n=5-6 animals).  
 
























































































































































































5.2.8. Intramuscular injection of bolus FTY720 stimulates pro-inflammatory 
immune cell infiltration 
Because of the atrophic effect of PLGA microparticles at week 9, we next 
investigated the effect of on-site delivery of FTY720 in the absence of biomaterial carriers. 
Bolus FTY720 (1 µg in 20 µL) was administered daily via intramuscular injection starting 
at the time of surgery, and immune cell infiltration was assessed at day 7 via flow 
cytometry. Daily FTY720 caused dramatically increased accumulation of MP (5.7-fold), 
MF (4.3-fold), MO (7.8-fold), and DC (3.8-fold) compared to vehicle control (Figure 36). 
FTY720 did not affect the proportion of M2-like or M1-like MF compared to vehicle 
(Figure 37a-c); however, both vehicle and FTY720 increased the proportion of 
CCR7+CD206- M1-like MF compared to uninjured contralateral controls (Figure 37d). 
FTY720 decreased the proportion of “dual-activated” MF that positively express both 
CD206 and CCR7 (Figure 37e), decreased the proportion of Ly6Clo non-classical MO  
(Figure 37f), and increased the proportion of Ly6Chi classical MO (Figure 37g). FTY720 
increased TH count (Figure 38a) and enrichment of T lymphocytes in TH subpopulation 
(Figure 38b) compared to both vehicle and uninjured contralateral controls. Daily FTY720 
did not affect blood levels of circulating MO (Figure 39a,b), but did cause lymphopenia 
with regard to both the TH and CD8+ cytotoxic T lymphocyte subpopulations of circulating 
T lymphocytes (Figure 37c,d). 
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Figure 36. Daily on-site delivery of bolus FTY720 affects mononuclear phagocyte 
infiltration. FTY720 dramatically increases accumulation of mononuclear phagocytes 
(A), macrophages (B), monocytes (C), and dendritic cells (D) in SS muscle at day 7 
compared to vehicle control and uninjured contralateral control. ***P<0.001, 
****P<0.0001 compared to uninjured contralateral control, ^^^P<0.001, ^^^^P<0.0001 
compared to vehicle control, as determined by two-way repeated measures ANOVA with 
post-hoc multiple comparisons test (n=5). 
 
 
Figure 37. Mononuclear phagocyte subpopulations after daily on-site delivery of 
FTY720. (A,B) M2-like macrophages, (C,D) M1-like macrophages, (E) CD206+CCR7+ 
dual-activated macrophages, (F) Ly6Clo non-classical monocytes, and (G) Ly6Chi classical 
monocyte frequencies within their respective parent populations at day 7. *P<0.05, 
**P<0.01, ***P<0.001 compared to uninjured contralateral control, ̂ P<0.05, ̂ ^^P<0.001, 
^^^^P<0.0001 compared to vehicle control, as determined by two-way repeated measures 










































































































































































Figure 38. CD4+ TH lymphocytes after daily on-site delivery of FTY720. (A) TH count 
and (B) TH frequency within the T lymphocyte pool are increased by FTY720 compared to 
vehicle control and uninjured contralateral control. *P<0.05, ***P<0.001 compared to 
uninjured contralateral control, ^^P<0.01, ^^^P<0.001 compared to vehicle control, as 




Figure 39. Immune cell count in blood circulation in response to RCT and daily on-
site delivery of FTY720. (A) Ly6Chi classical monocytes, (B) Ly6Clo non-classical 
monocytes, (C) CD4+ TH lymphocytes, and (D) CD8+ cytotoxic T lymphocytes. **P<0.01, 
***P<0.001, ****P<0.0001 compared to vehicle control as determined by two-way 
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RCT treatment responses are poor, as non-operative management fails in 
approximately 50% of patients, leaving surgical tendon repair as the standard of care[172, 
173]. The failure rate of surgery is as high as 26% for small to medium tears and up to 94% 
for large and massive tears[184-189]. Because muscle degeneration correlates highly with 
patient morbidities such as pain, functional deficiency, and post-surgical tear recurrence, 
prevention or reversal of muscle degeneration due to RCT could significantly improve 
treatment outcomes.  
By selectively targeting subpopulations of MP that are present in the injury niche 
of the torn RC, new interventions may be found that harness endogenous inflammatory 
signaling to promote repair. Our group and others have previously investigated this 
therapeutic approach in diverse injury models, including volumetric muscle loss[130], 
peripheral nerve regeneration[2], bone regeneration[57, 153, 183], microvascular network 
growth[6, 53], and cardiovascular injury[190]. Application of immuno-regenerative 
biomaterial strategies to treat RCT requires a foundational understanding the 
subpopulations present and their functions in this injury context. The present study 
represents the first detailed quantification of inflammatory cell populations in SS muscle 
and their role in degeneration. 
RCT injury causes dramatic infiltration of MP comprised of comparable 
frequencies of MF, MO, and DC. Injury skews the MF and MO pools toward non-classical 
CD206+ and Ly6Clo subpopulations, respectively, and away from the classical CCR7+ and 
Ly6Chi subpopulations. The impact of non-classical MF and MO on skeletal muscle has 
been partially elucidated in both acute and chronic injury contexts. After toxin-induced 
injury to skeletal muscle, CD206+ MF and Ly6Clo MO accumulate during the secondary 
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phase of healing and are required for complete regeneration, likely because they stimulate 
myotube fusion[1]. COX-2lo MF, which are phenotypically similar to CD206+ MF, protect 
myotubes against atrophy in vitro[191]. In contrast, classical Ly6Chi MO promote chronic 
muscle degeneration in mdx mice[192]. Taken together, these findings suggest that non-
classical MO and MF may support SS integrity compared to their classical counterparts 
that may feed forward degeneration. Here, depletion of circulating MO via liposomal 
clodronate accelerates SS atrophy. Because infiltration of circulating MO supplies the 
intramuscular MP pool[1], which is skewed toward non-classical MO and MF  after RCT, 
these results suggest that non-classical MO and MF may protect against SS degeneration. 
Therefore, interventions that decrease MP accumulation may exacerbate outcomes after 
RCT. Toward the ultimate goal of therapeutic immunomodulation, follow-up studies 
should employ gain- and loss-of-function techniques to elucidate the functions of non-
classical MO and MF in the context of SS degeneration and regeneration. Because these 
typically “pro-regenerative” MP subpopulations predominate the SS as early as day 7, 
increasing their recruitment may offer only modest therapeutic efficacy for muscle 
degeneration, which occurs over weeks.  
MO and MF infiltration of SS muscle is less pronounced after RCT compared to 
other muscle injury contexts[193]. MO and MF counts are 2.3x104 and 3.0x104 cells/g at 
day 7 following TT+DN. In degenerative muscles of the mdx mouse model of muscular 
dystrophy, MF counts vary from 6x104 to 3x106 cells/g at 6-12 weeks of age[192, 194]. 
After toxin-induced skeletal muscle injury, MO/MF infiltration is dramatically higher, 
reaching a maximum of 1.4x107 cells/g at day 7[155]. Myocardial infarction results in 
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massive infiltration of 4.5x107 Ly6Chi and 3.0x107 Ly6Clo MO/g at days 3 and 5-7, 
respectively[8]. Notably, the preceding examples involve direct injury to the muscle, 
whereas the RCT model herein primarily involves injury to tendon and nerve, with 
subsequent effects on rotator cuff muscles.  That RCT results in less infiltration of MP 
compared to other muscle pathologies suggests that the underlying inflammatory stimuli 
may be less severe.  
The present study represents a snap shot of the immune cell profile, which may 
change dynamically over time. The day 7 time point was selected because robust MP 
infiltration is detected at day 7 in numerous studies of soft tissue injury[6, 27, 130]. 
Evaluating multiple time points earlier and later than day 7 would elucidate whether the 
magnitude and phenotypic distribution of MP infiltration evolves temporally after RCT. 
Infiltration of non-classical subpopulations after TT+DN injury was associated 
with increased production of pro-regenerative proteins, namely IL-10, IL-33, SDF-1α, 
IGF-1, Dkk-1, and basic FGF (bFGF). IL-10 is produced by non-classical monocytes and 
M2b and M2c macrophages, and polarizes MF toward M2c “regulatory macrophage” 
phenotype[10, 11]. IL-10 blunts inflammation by inhibiting the production and activity of 
various pro-inflammatory cytokines[11], and IL-10 switches muscle MF from a pro-
inflammatory M1 to reparative M2 phenotype that promotes muscle regeneration after 
acute injury[195]. Local IL-33 rescues aged mouse impairment in Treg accumulation and 
acute muscle regeneration[20]. As described earlier, SDF-1α is involved in the recruitment 
of non-classical MO, and increased SDF-1α expression is associated with wound healing 
in various tissues[196]. IGF-1 down-regulates pro-inflammatory cytokines such as TNFα 
and IL-1β, accelerates muscle regeneration, and reduces muscle fibrosis[197]. MF-specific 
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expression of IGF-1 is required for acute muscle regeneration; after acute muscle injury, 
MF secrete IGF-1 which autopolarizes them toward reparative gene programs[63]. Wnt 
signlaing is in part responsible for the fibrotic bias of satellite cells during muscle healing 
in aged mice[198]. Intramuscular injection of dkk-1, an endogenous protein inhibitor of 
canonical Wnt signaling, reduces fibrosis in aged mice after acute muscle injury and in 
mdx mice[199]. Basic FGF (bFGF) promotes myoblast proliferation yet inhibits myoblast 
differentiation in vitro, and thus may promote the early phase of muscle regeneration[200]. 
Elevated bFGF is found in serum and muscles during chronic muscle degeneration in 
humans and mice with muscular dystrophy[201, 202]. Taken together, the results suggest 
that the cytokine and growth factor milieu in SS muscle after RCT is generally conducive 
to regeneration.  
The ideal injury paradigm for pre-clinical investigation of RCT is controversial. 
Specifically, it is unclear whether denervation is an appropriate adjunct injury to tenotomy 
for modeling human pathogenesis. Clinically, the relationship between tendinopathy, 
suprascapular neuropathy, and muscle degeneration is unclear. Suprascapular neuropathy 
is present in only 8-12% of patients with full-thickness RCTs[203-207] and is likely caused 
by muscle retraction and increased tension on the suprascapular nerve[208]. Clinical 
studies contradict each other as to whether RCT-induced suprascapular neuropathy 
contributes to muscle degeneration[205, 209]. Nevertheless, in pre-clinical models, 
suprascapular denervation helps recapitulate the degree of muscle degeneration observed 
in human cases of RCT[69, 181, 182, 210]. In the present study, TT+DN increases MP, 
MO, and DC counts by at least 2-fold and slightly increases CD206+ enrichment of the MF 
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pool compared to TT. These results show that inflammatory infiltrate in SS muscle is 
affected dramatically by denervation as an adjunct to tenotomy. 
The biological cascade connecting RCT-induced muscle unloading to chronic 
muscle degeneration is unknown. Given that muscle anabolism and catabolism are coupled 
to physical activity[211], mechanical unloading after RCT likely causes myofiber atrophy 
by shifting muscle metabolism from anabolic to catabolic processes. The initial hypothesis 
of the present study is that MP infiltration exacerbates SS atrophy. According to this 
hypothesis, muscle unloading after RCT causes mitochondrial dysfunction[212], 
elaboration of damage associated molecular patterns (DAMPs), and recruitment of 
inflammatory cells that secrete pro-inflammatory cytokines (e.g. TNFα, IL-1β, IL-6)[8, 11, 
23, 24], which then stimulate catabolism of intramyocellular proteins over weeks[65]. 
However, results here suggest that MP infiltration protects against SS atrophy in mice. 
Future studies are required to elucidate the etiology of RC muscle degeneration. 
 The impact of subpopulations of T lymphocytes on skeletal muscle is increasingly 
recognized. In agreement with the report that T lymphocytes are dispensable for the 
development of fatty degeneration in rats[67], RCT does not affect T lymphocyte count in 
mouse SS muscle. However, RCT enriches the T lymphocyte pool in TH and Treg 
subpopulations.  Multivariate analysis reveals injury type-specific differences in T 
lymphocyte populations not detected by individual measurements; TT+DN is 
discriminated from TT by increased overall T lymphocyte frequency and decreased Treg 
frequency within the TH pool. TH are required for biomaterial-induced non-classical MF 
polarization and muscle regeneration after volumetric muscle loss[28]. Treg aid repair of 
acutely injured skeletal muscle, possibly because they encourage MP to switch from 
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classical to non-classical phenotypes[213]. Deficient Treg accumulation in aged mice 
impairs acute muscle regeneration[20]. Thus, enrichment of the TH and Treg fractions may 
confer protective effects on SS muscle after RCT. Moving forward, one intriguing 
hypothesis is that aging may exacerbate RCT-induced muscle degeneration due to deficient 
accumulation of TH or Treg subpopulations. 
SDF-1α-releasing, hydrolytically degradable Hep-N-PEGDA microparticles were 
injected into SS muscle at the time of RCT injury to test the hypothesis that local delivery 
of SDF-1α would recruit non-classical MO at the acute week 1 time point. SDF-1α skewed 
the MF pool toward dual expression of the M1 (CCR7) and M2 (CD206) markers. There 
are no reported functions in vitro or in vivo of this dual polarized phenotype. Dual 
CD206+CCR7+ polarization possibly reflects the highly plastic nature of MF and their 
ability to integrate a multitude of microenvironmental signals, which may consist of pro-
inflammatory and anti-inflammatory cues simultaneously. Future studies could employ 
single cell qPCR to compare the function of dual polarized MF to other MF 
subpopulations via broad gene expression. 
Subsequent studies of therapeutic drug delivery pivoted to local delivery of 
FTY720-encapsulating PLGA microparticles for multiple reasons. First, data from SDF-
1α delivery did not suggest unambiguous pro-regenerative effects on immune cell 
recruitment. Second, our lab previously showed that FTY720 stimulation of MO in vitro 
and injured skin in vivo causes cytokine secretion to shift the balance from pro-
inflammatory to pro-regenerative factors. Lastly, Hep-N microparticles exhibit rapid release 
of FTY720 by 24 h, whereas PLGA microparticles can sustain the release of FTY720 over 
multiple weeks. 
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At the early week 1 time point, FTY720 release from PLGA microparticles 
decreases the frequency of Treg within the TH and T cell populations. Decreased Treg 
frequency may be caused by multiple processes, including decreased recruitment, 
proliferation, survival, retention, or differentiation of Treg, or an increase in these 
processes in other T lymphocyte populations. In light of literature reporting pro-
regenerative effects of Treg on skeletal muscle, decreased Treg frequency caused by 
FTY720 may exacerbate muscle degeneration. At the late week 9 time point, FTY720 
release had no significant effect on SS atrophy, whereas control PLGA microparticles 
exacerbated atrophy. PLGA microparticles increased accumulation of macrophages, 
particularly CD206+ M2-like macrophages. SS atrophy did not correlate with CD206+ 
macrophage count, suggesting that CD206+ macrophages likely do not exert atrophic 
effects on SS muscle. The acidic products of PLGA degradation, lactic acid and glycolic 
acid, may negatively regulate muscle mass[214], but additional experiments would be 
necessary to test this hypothesis. 
To investigate on-site FTY720 in the absence of atrophic PLGA microparticles, 
bolus FTY720 was injected into SS muscle daily. FTY720 exhibited broad pro-
inflammatory effects, increasing the accumulation of all MP populations, increasing the 
frequency of classical MO, and decreasing the frequency of non-classical MO. 
Interestingly, bolus FTY720 decreased the frequency of CD206+CCR7+ dual polarized 
MF, similar to the effect of SDF-1α delivery from Hep-N microparticles. FTY720-induced 
patterns of MP accumulation were unlikely to result from systemic effects on circulating 
MO, given that blood counts of classical and non-classical MO did not differ between 
FTY720 and control. FTY720 dramatically increased TH accumulation despite causing 
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lymphopenia in blood. Divergent immunomodulatory effects due to daily injection versus 
sustained polymeric release of FTY720 may be explained by additional injury stimuli 
introduced by injections. Repeated injections likely injure myofibers, thereby creating a 
profile of DAMPs, cytokines, and endothelial adhesion signatures that differ from SS 
muscle experiencing indirect injury via tendon and nerve transection.  
Inability of local delivery of SDF-1 and FTY720 to induce pro-regenerative cell 
recruitment and protein production after murine RCT contrasts with prior studies 
indicating such effects in the murine dorsal skin window model[6, 27, 215]. The disparity 
may suggest that the effects of SDF-1 and FTY720 on inflammation are highly context-
dependent. Moreover, given that the murine SS is biased naturally toward non-classical 
monocyte/macrophage subpopulations and regenerative proteins after RCT, the 
therapeutic window for immune modulation may be limited. To identify additional 
therapeutic targets, deeper investigation of the mechanisms underlying SS degeneration 
and regeneration are necessary. 
  
5.4. Materials and Methods 
5.4.1. Mouse model of massive rotator cuff injury 
All animal procedures were conducted according to protocols approved by the 
Georgia Tech Institutional Animal Care and Use Committee. Male C57bl/6 mice aged 8 
weeks were anesthetized using vaporized isoflurane (5% for induction and 2% for 
maintenance). Sustained-release buprenorphine was administered i.p. for analgesia. The 
right shoulder served as the injured group and the contralateral shoulder served as the 
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uninjured control group. The right arm and chest were shaved, depilated, and sterilized 
using triplicate alternating washes of alcohol and chlorhexidine. Using a No. 11 scalpel 
blade, a lateral incision in the skin was made from the midline to the humeral head. Fascia 
was removed by blunt dissection. To expose the glenohumeral joint, the deltoid was split 
by making a ~5mm incision from the clavicle to the superior-lateral region of the humerus. 
The supraspinatus and infraspinatus tendons were sharply transected using the scalpel 
blade. The suprascapular nerve (SSN) was located by creating a small incision in the 
pectoralis major and bluntly dissecting the muscle. The SSN was severed using surgical 
microscissors. The deltoid and pectoralis were closed using absorbable 4-0 sutures and the 
skin was closed using wound clips. Mice were allowed unrestricted ambulation after 
awakening from anesthesia. 
 
5.4.2. Flow cytometry 
For blood analysis, blood samples were collected via retro-orbital sinus. For SS 
muscle analysis, mice were euthanized by CO2 asphyxiation 7 days after injury to analyze 
cellular inflammation in the muscle. To generate single cell suspensions from blood, RBCs 
were lysed by suspension in ammonium chloride for 10 min. To generate single cell 
suspensions from muscles, tissue was minced, digested in 1mg/mL collagenase IA for 45 
min at 37°C, filtered through membranes with 40µm pore size, and resuspended in 3% FBS 
for immunostaining. Cell suspensions were immunostained for 30 min on ice followed by 
fixation in 2% PFA for 10 min and addition of CountBrightTM Absolute Counting Beads. 
The following antibody panel was used: MerTK-PE (clone 108928; R&D Systems), 
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CCR7-PE/Cy7 (clone 4B12; BioLegend), CD3-FITC (17A2; BioLegend), CD25-
PerCP/Cy5.5 (clone PC61; BioLegend), Ly6C-APC (clone HK1.4, BioLegend), Ly6G-
APC/Cy7 (clone 1A8; BioLegend), CD11c-BV421 (clone N418; BioLegend), CD11b-
BV510 (clone M1/70; BioLegend), CD206-BV605 (clone C068C2; BioLegend), CD64-
BV711 (clone X54-5/7.1; BioLegend), and CD4-BV785 (clone GK1.5; BioLegend). To 
discriminate positive versus negative expression of each marker, the fluorescence-minus-
one (FMO) approach was used. Briefly, excess cell suspension was immunostained with 
all antibodies except the marker of interest. The threshold of positive versus negative 
expression of the marker of interest was then set at the level of the most highly fluorescent 
events in the marker’s corresponding channel. Samples were run on a BD FACS Aria IIIu 
cytometer and data was analyzed using FlowJo software. Cells were immunophenotyped 
according to the following gating scheme: macrophage, MerTK+CD64+; dendritic cell, 
NOT(MerTK+CD64+)CD11c+; monocyte, NOT(MerTK+CD64+)CD11c-CD11b+SSClo; 
neutrophil, Ly6G+SSChi; T lymphocyte, CD3+; helper T lymphocyte, CD3+CD4+; 
regulatory T lymphocyte, CD3+CD4+CD25+. Metrics reporting cell count normalized to 
muscle mass were calculated according to the equation N = Ng*Ba/(Bm*M), where Ng is 
the number of cells counted in the gate-of-interest, Ba is number of counting beads added 
to the sample, Bm is the number of counting beads measured by the cytometer, and M is 
the wet muscle mass. Metrics reporting frequency were calculated by dividing the number 
of cells in the gate-of-interest by the number of cells in a particular upstream gate.  
 
5.4.3. Principal component analysis 
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Unsupervised principal component analysis was performed using Matlab. The 
following 11 variables from flow cytometry were used as inputs to the model: muscle mass, 
MF (% of cells), MO (% of cells), DC (% of cells), T lymphocyte (% of cells), neutrophil 
(% of cells), CD206+ (% of MF), CCR7+ (% of MF), Ly6Clo (% of MO), TH (CD4+CD3+ 
% of CD3+), and Treg (CD25+CD4+CD3+ % of CD4+CD3+). Ly6Chi (% of MO) was 
omitted because the value equals 1 – Ly6Clo. Data were scaled to unit variance and mean 
centered. Regarding quality of fit, Hoetelling’s T2 and DModX are less than critical values 
for all observations. For PC1, R2 = 0.575 and Q2 = 0.431. For PC2, R2 = 0.166 and Q2 = 
0.064. 
 
5.4.4. Clodronate-liposome administration and myofiber diameter analysis 
Intravenous administration of liposomal clodronate causes complete depletion of 
blood MO within 6 h followed by recovery of the Ly6Chi and Ly6Clo MO populations at 2 
and 7 days, respectively[178]. To deplete circulating monocytes in the present study, 
liposomal clodronate (100µL per 10g of body weight; Dr. Nico van Rooijen, 
clodronateliposomes.org) or saline control was administered i.v. via jugular vein injection 
every 2-3 days according to the timeline in Figure 32. Supraspinatus atrophy was assessed 
by wet mass and IHC analysis of myofiber cross-sectional area at day 21 post-injury. To 
prepare muscles for IHC, mouse vasculature was perfused with 0.9% saline followed by 
4% paraformaldehyde and then muscles were harvested and snap frozen in liquid nitrogen-
cooled 2-methylbutane. Muscle cross-sections (thickness: 10 µm) were acquired using a 
cryostat (Leica CryoStar NX70). Immunohistochemistry was performed on cross-sections 
 126 
by staining with goat anti-collagen IV (Millipore AB769) and donkey anti-goat conjugated 
to DyLight 594 (abcam ab96933). Fluorescence was visualized at 594 nm excitation using 
a Zeiss LSM 710 NLO confocal microscope. Regions of interest were selected to include 
most of the muscle cross-section interior and exclude the periphery. Semi-automated 
quantification of myofiber diameter was performed in ImageJ by manually thresholding 
pixel intensity, automatically detecting edges using the “Find Edges” process, and 
quantifying diameter of each myofiber using the “WandAutoMeasure” tool. To account for 
variation in number of myofibers quantified, equal numbers of myofibers were randomly 
selected from each animal, pooled, and subjected to statistical analysis (n=964 across 4 
animals per group). 
 
5.4.5. Hep-N microparticle fabrication 
10 wt% Hep-N microparticles were fabricated via water-and-oil single emulsion. 
50.0 mg PEGDA and 0.92-1.85 mg dithiothreitol (DTT, 20-40 mM, Sigma) were added to 
273 µL 10 wt% bovine serum albumin (BSA, Thermo) solution in PBS and incubated at 
37°C for 30 mins to allow for Michael-type addition between PEGDA and DTT.  Next, 5.6 
mg Hep-NMAm was added and the aqueous phase was incubated for an additional 30 mins.  
 27 µL of 0.05 wt% Irgacure 2959 photoinitiator (Ciba) was added, and the aqueous 
phase was pipetted drop-wise into an oil phase containing 5 mL mineral oil (Amresco) and 
3.0-3.2 µL Span80 (TCI). The mixture homogenized at 4000 RPM (Polytron PT 3100, 
Kinematica) for 5 mins.  The water-and-oil emulsion was nitrogen purged for 1 min and 
treated with UV irradiation (~15 mW/cm2) for 10 mins to enable free radical 
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polymerization between PEGDA and Hep-NMAm.  Finally, the microparticle solution was 
separated from the oil phase by centrifugation and washed with dH2O, then pipetted 
through 40 µm porous membrane strainers to remove microparticles under 40 µm in 
diameter.   
 Once fabricated, microparticles were sterilized in 70% ethanol for 30 mins and 
washed in sterile PBS.  MPs were imaged via phase microscopy.  Microparticles were 
stored in sterile PBS at 4°C and used within 2 weeks of fabrication. 
 
5.4.6. SDF-1α loading and release from Hep-N microparticles 
To load SDF-1a onto Hep-N microparticles, 1.0-1.2 µg human SDF-1a (R&D 
Systems) was added to 0.6 mg MPs in 50 µL 0.1 wt% BSA solution and incubated for 2 
hours at 4°C, after which time microparticles were rinsed by adding an additional 450 µL 
0.1 wt% BSA solution.  Microparticles were centrifuged for 3 mins at 10,000 RCF and 495 
µL supernatant was removed.   
 For in vitro SDF-1a release studies, the removed supernatant was replaced with 
fresh 0.1 wt% BSA solution and samples were incubated at 37°C until designated time 
points, when media was exchanged for protein analysis.  SDF-1a protein was quantified 
using a human SDF-1a ELISA kit (R&D Systems). 
 
FTY720-loaded PLGA microparticle fabrication 
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 FTY720-loaded PLGA microparticles were fabricated using established single 
emulsion technique. Briefly, FTY720 (Cayman Chemical) dissolved in DMSO (20 
mg/mL) was mixed at a mass ratio of 1:70 (9 week study) or 1:150 (7 day study) with 
PLGA (50:50 copolymer ratio) dissolved in methylene chloride (20% wt/v). Polymer 
solution was added dropwise to poly(vinyl alchohol) solution (2% w/v, aqueous) under 
constant homogenization at 4000 RPM for 1 min. Resultant microparticle suspension was 
stirred for 3 h to evaporate solvent, sieved through a porous membrane (40 µm pore size) 
to isolate particles larger than 40 µm, and washed 3 times in deionized water. Control 
PLGA microparticles were fabricated using the same process but with FTY720 absent from 
the initial DMSO solution. For in vivo studies, equivalent fractions of the total batch 
volume were taken from FTY720 and PLGA microparticle batches. 
 
In vitro release of FTY720 from PLGA microparticles 
 FTY720-encapsulating PLGA microparticles were suspended in simulated body 
fluid with 4% fatty acid-free BSA and incubated at 37°C. Media was exchanged at 
designated time points to quantify FTY720. FTY720 was isolated from samples by lipid 
extraction. Briefly, samples were added to 2:1 CH3OH:CHCl3 solution and heated at 48°C 
overnight. Glycerophospholipids were degraded by heating at 37C for 2 h in the presence 
of KOH. The pH was neutralized with acetic acid, solvent was evaporated using a 
SpeedVac concentrator, and samples were dissolved in 72:29:1 CH3OH:H2O:HCOOH 
solution. For LC-MS/MS analysis, samples were injected into a C18 chromatography 
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column upstream of a Micromass Quattro LC triple quadrupole tandem mass spectrometer 
operating under electrospray ionization. 
  
Intramuscular injection of therapeutics 
 Microparticles (20 µL volume) were injected directly into the SS muscle during 
surgery using insulin syringe. To administer soluble FTY720 daily, mice were anesthetized 
with vaporized isoflurane, the scapula was gently restrained, the insulin syringe was passed 
through the skin into the SS muscle, and FTY720 solution (20 µL sterile saline) was 
injected. 
 
Multiplex cytokine immunoassay 
 SS muscles were minced, disaggregated physically in the presence of 
protease/phosphatase inhibitor, and lysed using cell lysis buffer (Cell Signaling 
Technology) for 45 min on ice.  Protein supernatant was isolated after centrifugation at 
14000 RPM for 15 min. A custom 22-plex protein immunoassay kit (R&D Systems) was 
used to quantify key cytokines and growth factors using Luminex MAGPIX® system.  
Each sample was run in duplicate and averaged. BCA assay was used to quantify total 




 Muscles were snap frozen in liquid nitrogen-cooled isopentane, and frozen sections 
(10 µm thick) were acquired from the muscle belly via cryostat. Sections were blocked 
with 5% mouse serum for 1 h, washed, incubated with rat anti-mouse CD68-AF647 (1:200, 
AbSerotec) and CD206-AF488 (1:200, AbSerotec) in 2.5% mouse serum overnight at 4°C, 
washed, and mounted with Vectashield. Z-stacked confocal images were acquired using a 
Zeiss 710 NLO confocal microscope. To quantify CD68+ MF and CD206+CD68+ M2-like 
MF, two representative regions of interest were selected in each section and cells were 
counted manually based on fluorescence intensity. 
 
5.4.7. Statistical analysis 
In Figure 26, Figure 27, Figure 28, and Figure 29, statistical comparisons were 
conducted in GraphPad Prism using repeated measures two-way ANOVA followed by 
Sidak multiple comparisons test. Figure 32 was analyzed by t-test (Panel c) and Mann-
Whitney test (Panel e,f,g). 
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6. FUTURE DIRECTIONS 
6.1. Immune cell characterization 
While the present studies utilize well-accepted paradigms to characterize 
mononuclear phagocyte phenotypes, the field of immune biology continues to elucidate 
additional layers of heterogeneity and complexity within the mononuclear phagocyte 
system. For example, multiple subpopulations of M2 macrophages (M2a, b, c) have been 
identified from divergent polarization schemes in vitro. Future work could employ 
intracellular cytokine staining and additional extracellular markers to distinguish between 
M2a-c subpopulations. Nevertheless, it is unclear how well immunophenotypes in vitro 
describe cell functions in vivo. Macrophages integrate myriad signals in their 
microenvironment and are highly plastic cells. To determine changes in macrophage 
function and phenotype in vivo in response to perturbation, future studies could employ 
high-dimensional, single-cell analytical techniques such as single-cell qPCR and highly 
multiplexed mass cytometry. By analyzing a panel of genes governing established and 
putative macrophage functions, single-cell qPCR would enable evaluation of cell function 
at the transcription level and, using hierarchical clustering, identification of potentially 
novel functional subpopulations. Highly multiplexed mass cytometry may also enable 
identification of novel subpopulations at the level of surface marker expression. 
 
6.2. Fractalkine aptagels 
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Future directions of the aptagel platform include further mechanistic investigation, 
material modifications, and evaluation in more clinically-relevant animal models. 
Although the present study demonstrated enrichment of endogenous fractalkine within 
aptagels, the gradient within surrounding tissue was unknown. Additional experiments 
could investigate the spatiotemporal dynamics of the endogenous fractalkine gradient using 
concentric biopsies and ELISA. 
Toward the goal of clinical translation, future studies could employ computational 
modelling or experimentation with mutated or modified aptamers[86, 126] to identify if 
better enrichment kinetics exist and to enable enrichment of hFKN. The ability to alter 
formulations may enable application to diverse clinical contexts. For example, aptabeads 
or aptamer-functionalized nanoparticles[146] may be advantageous when injury occurs 
deep within tissue and bulk hydrogel implantation is not feasible, such as after brain injury 
(e.g. trauma or stroke). Elevated FKN is associated with improved healing after brain 
injury[80-82] but while FKN concentration rises initially and drives CX3CR1+ cell 
recruitment, FKN levels soon fall rapidly[127]. FKN-aptabeads could prolong CX3CR1+ 
cell recruitment by storing FKN during the early surplus and releasing it during later days 
as FKN levels decline. Other critical molecules can be targeted by identifying binding 
aptamers via SELEX and tuning aptamer kinetics via selection pressures, mutations, 
truncations, and additions[86]. Through this, combinations of aptamers could be 
immobilized on biomaterials to treat complex pathological conditions in which regulation 
or enrichment of multiple proteins is required. Lastly, DNAse dampened fractalkine-
binding functionality in vitro in the present study, suggesting that incorporation of DNAse 
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resistant bases may further amplify FKN enrichment and consequent recruitment of 
CX3CR1+ cells.  
 
6.3. Heparin-functionalized hydrogels 
To leverage the proangiogenic/proarteriogenic effects of heparin-functionalized 
hydrogels toward major unmet clinical indications, future studies could evaluate this 
platform in more rigorous and clinically-relevant animal models. Chronic ischemic 
pathologies, such as peripheral and cardiac arterial disease, are strategic targets because 
therapeutic arteriogenesis restores perfusion and because no existing therapies induce 
durable perfusion. Hindlimb ischemia via arterial ligation is the standard animal model of 
peripheral arterial disease. Future work could test whether local, intramuscular delivery of 
SDF-1 and/or FTY720 from degradable heparin-functionalized microparticles stimulates 
hindlimb arteriogenesis and perfusion. The proangiogenic hydrogel platform may also 
prove efficacious in wound healing indications in which neovascularization is critical, such 
as massive trauma to peripheral nerve, bone, and muscle. Broader applications include 
other contexts in which recruitment of anti-inflammatory immune cell subsets may be 
therapeutic by inducing tolerance or resolving inflammation, such as vascularized 
composite allografts (VCA), chronic cutaneous wounds, and chronic inflammatory 
diseases amenable to biomaterial implantation. 
 
6.4. Muscle degeneration due to rotator cuff tear 
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Future studies related to rotator cuff injury should address outstanding questions 
about underlying immune biology, utilize a more clinically relevant injury paradigm, and 
investigate promising alternative immunomodulatory therapeutics. To assess how specific 
subpopulations affect rotator cuff muscle degeneration, loss- and gain-of-function 
techniques could be employed. The role of each circulating monocyte subpopulation can 
be implicated using CCR2-/- and NR4A1-/- transgenic mice, which present reduced 
circulating levels of Ly6Chi classical and Ly6Clo non-classical monocytes, respectively. 
To determine molecular mechanisms by which inflammation affects degeneration, putative 
catabolic cytokines (e.g. TNFα) could be knocked down via administration of siRNA, 
neutralizing antibodies, or small molecule inhibitors. Specific cell populations could be 
implicated in the production of degenerative factors via transgenic mice lacking expression 
of a target gene in a specific cell lineage; for example, crossing Csf1rcre mice with Il6fl/fl 
mice yields offspring lacking expression of IL-6 in monocytes and macrophages. Gain-of-
function techniques include intramuscular injection of cytokines or macrophages pre-
polarized toward divergent phenotypes such as M1 vs. M2a-c. The biological cascade 
connecting RCT-induced muscle unloading to chronic muscle degeneration is unknown. 
Given that muscle anabolism and catabolism are coupled to physical activity, mechanical 
unloading after RCT likely causes myofiber atrophy by shifting muscle metabolism from 
anabolic to catabolic processes. Future studies could investigate an immune-centric 
hypothesis whereby muscle unloading after RCT causes mitochondrial dysfunction, 
elaboration of damage associated molecular patterns (DAMPs), and recruitment of 
inflammatory cells that secrete factors that may have degenerative and/or protective 
effects. 
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Recapitulation of human disease characteristics in animal models is critical to 
improve the likelihood that preclinical data provide meaningful insight into clinical 
biology. In the present studies of rotator cuff injury, potential treatments are evaluated for 
their ability to modulate inflammation and protect against denaturation when the tendon 
and nerve remain transected. Although slowing degeneration is desirable, it is unlikely that 
therapeutic perturbations will produce durable responses in the absence of mechanical 
loading and innervation. In the clinic, diagnosis of RCT occurs late when muscle 
degeneration is progressed. The clinical treatment paradigm of muscle-focused therapies 
is likely to involve surgical tendon reattachment followed by intramuscular injections. 
Future studies should utilize rats or rabbits to investigate an experimental paradigm in 
which supraspinatus muscle is allowed to degenerate chronically after tenotomy and then 
reattached prior to treatment. To further increase translational relevance of the project, 
human muscle biopsy samples could be compared to rodents. Single cell qPCR analysis 
would provide high-dimensional insight into the phenotype and function of immune cells 
in human supraspinatus. Given the modest effects of SDF-1/FTY720 delivery in these 
rotator cuff studies, future work should investigate additional candidate therapeutics. For 
example, delivery of pro-resolving lipid mediators such as resolvin D1 (RvD1) has shown 
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